Loading...

Peter Carroll, MD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentUrology
Address550 16th. Street
San Francisco CA 94158
Phone415-353-7098
vCardDownload vCard
    Other Positions
    TitleChair, Urology


    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoResidency School of Medicine -Urology

    Collapse Research 
    Collapse Research Activities and Funding
    Effectiveness of Early Stage Prostate Cancer Treatment
    NIH/NCI RC1CA146596Sep 30, 2009 - Aug 31, 2012
    Role: Principal Investigator
    UCSF KURe Career Development Program
    NIH/NIDDK K12DK083021Sep 30, 2008 - Jul 31, 2018
    Role: Co-Principal Investigator
    Male Reproductive Health Research Career Development Program
    NIH/NICHD K12HD053943Sep 30, 2006 - Aug 31, 2012
    Role: Principal Investigator
    Active Surveillance for Early Stage Prostate Cancer: Selection, Monitoring
    NIH/NCI R13CA121759May 5, 2006 - Apr 30, 2007
    Role: Principal Investigator
    Molecular Effects of Nutrition Supplements in Prostate
    NIH/NCI R01CA101042Jun 10, 2003 - May 31, 2009
    Role: Principal Investigator
    UCSF PROSTATE CANCER SPORE
    NIH/NCI P50CA089520Sep 25, 2000 - Jun 30, 2010
    Role: Principal Investigator
    Cancer Center Support Grant
    NIH/NCI P30CA082103Aug 5, 1999 - May 31, 2018
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet C, Tameire F, Evans MJ, Evans CP, Yang JC, Hann B, Koumenis C, Walter P, Carroll P, Ruggero D. Development of a stress response therapy targeting aggressive prostate cancer. Sci Transl Med. 2018 May 02; 10(439). PMID: 29720449.
      View in: PubMed
    2. Kearns JT, Faino AV, Newcomb LF, Brooks JD, Carroll P, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y, Lin DW. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. Eur Urol. 2018 Feb 09. PMID: 29433973.
      View in: PubMed
    3. Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll P, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. Eur Urol. 2018 Feb 09. PMID: 29433975.
      View in: PubMed
    4. Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll P, Karnes RJ, Spratt DE, Feng FY. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 2017 12 01; 3(12):1663-1672. PMID: 28494073.
      View in: PubMed
    5. Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll P, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL. Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. J Clin Oncol. 2018 Feb 20; 36(6):581-590. PMID: 29185869.
      View in: PubMed
    6. Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll P, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R. Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. Ann Intern Med. 2018 Jan 02; 168(1):1-9. PMID: 29181514.
      View in: PubMed
    7. Tat D, Kenfield SA, Cowan JE, Broering JM, Carroll P, Van Blarigan EL, Chan JM. Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSURE™). Prostate. 2018 Jan; 78(1):32-39. PMID: 29105845.
      View in: PubMed
    8. Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg MR, Carroll P. Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa). PLoS One. 2017; 12(10):e0185535. PMID: 29016610.
      View in: PubMed
    9. Zhou CK, Stanczyk FZ, Hafi M, Veneroso CC, Lynch B, Falk RT, Niwa S, Emanuel E, Gao YT, Hemstreet GP, Zolfghari L, Carroll P, Manyak MJ, Sesterhenn IA, Levine PH, Hsing AW, Cook MB. Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers. Prostate. 2017 Dec; 77(16):1573-1582. PMID: 28971497.
      View in: PubMed
    10. Starobinets O, Simko JP, Kuchinsky K, Kornak J, Carroll P, Greene KL, Kurhanewicz J, Noworolski SM. Characterization and stratification of prostate lesions based on comprehensive multiparametric MRI using detailed whole-mount histopathology as a reference standard. NMR Biomed. 2017 Dec; 30(12). PMID: 28961382.
      View in: PubMed
    11. Lake ST, Greene KL, Westphalen AC, Behr SC, Zagoria R, Small EJ, Carroll P, Hope TA. Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. EJNMMI Res. 2017 Sep 19; 7(1):77. PMID: 28929350.
      View in: PubMed
    12. Welty CJ, Sanford TH, Wright JL, Carroll P, Cooperberg MR, Meng MV, Porten SP. The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy. Cancer. 2017 Dec 01; 123(23):4574-4582. PMID: 28881475.
      View in: PubMed
    13. Leapman MS, Wang ZJ, Behr SC, Kurhanewicz J, Zagoria RJ, Carroll P, Westphalen AC. Impact of the integration of proton magnetic resonance imaging spectroscopy to PI-RADS 2 for prediction of high grade and high stage prostate cancer. Radiol Bras. 2017 Sep-Oct; 50(5):299-307. PMID: 29085163.
      View in: PubMed
    14. Cook MB, Stanczyk FZ, Wood SN, Pfeiffer RM, Hafi M, Veneroso CC, Lynch B, Falk RT, Zhou CK, Niwa S, Emanuel E, Gao YT, Hemstreet GP, Zolfghari L, Carroll P, Manyak MJ, Sesterhann IA, Levine PH, Hsing AW. Relationships between Circulating and Intraprostatic Sex Steroid Hormone Concentrations. Cancer Epidemiol Biomarkers Prev. 2017 Nov; 26(11):1660-1666. PMID: 28830872.
      View in: PubMed
    15. Osterberg EC, Palmer NRA, Harris CR, Murphy GP, Blaschko SD, Chu C, Allen IE, Cooperberg MR, Carroll P, Breyer BN. Outcomes of men on active surveillance for low-risk prostate cancer at a safety-net hospital. Urol Oncol. 2017 Nov; 35(11):663.e9-663.e14. PMID: 28826701.
      View in: PubMed
    16. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll P. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2017 Dec; 58(12):1956-1961. PMID: 28522741.
      View in: PubMed
    17. Herlemann A, Cowan JE, Carroll P, Cooperberg MR. Community-based Outcomes of Open versus Robot-assisted Radical Prostatectomy. Eur Urol. 2018 Feb; 73(2):215-223. PMID: 28499617.
      View in: PubMed
    18. Fulgham PF, Rukstalis DB, Turkbey IB, Rubenstein JN, Taneja S, Carroll P, Pinto PA, Bjurlin MA, Eggener S. AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2017 Oct; 198(4):832-838. PMID: 28483574.
      View in: PubMed
    19. Masic S, Washington SL, Carroll P. Management of intermediate-risk prostate cancer with active surveillance: never or sometimes? Curr Opin Urol. 2017 May; 27(3):231-237. PMID: 28234748.
      View in: PubMed
    20. Van Blarigan EL, Kenfield SA, Tantum L, Cadmus-Bertram LA, Carroll P, Chan JM. The Fitbit One Physical Activity Tracker in Men With Prostate Cancer: Validation Study. JMIR Cancer. 2017 Apr 18; 3(1):e5. PMID: 28420602.
      View in: PubMed
    21. Kim CS, Lee JY, Chung BH, Kim WJ, Fai NC, Hakim L, Umbas R, Ong TA, Lim J, Letran JL, Chiong E, Wu TL, Lojanapiwat B, Türkeri L, Murphy DG, Gardiner RA, Moretti K, Cooperberg M, Carroll P, Mun SK, Hinotsu S, Hirao Y, Ozono S, Horie S, Onozawa M, Kitagawa Y, Kitamura T, Namiki M, Akaza H. Report of the Second Asian Prostate Cancer (A-CaP) Study Meeting. Prostate Int. 2017 Sep; 5(3):95-103. PMID: 28828352.
      View in: PubMed
    22. Leapman MS, Cowan JE, Nguyen HG, Shinohara KK, Perez N, Cooperberg MR, Catalona WJ, Carroll P. Active Surveillance in Younger Men With Prostate Cancer. J Clin Oncol. 2017 Jun 10; 35(17):1898-1904. PMID: 28346806.
      View in: PubMed
    23. Vertosick EA, Vickers AJ, Cowan JE, Broering JM, Carroll P, Cooperberg MR. Interpreting Patient Reported Urinary and Sexual Function Outcomes across Multiple Validated Instruments. J Urol. 2017 Sep; 198(3):671-677. PMID: 28342935.
      View in: PubMed
    24. Moschini M, Carroll P, Eggener SE, Epstein JI, Graefen M, Montironi R, Parker C. Low-risk Prostate Cancer: Identification, Management, and Outcomes. Eur Urol. 2017 Aug; 72(2):238-249. PMID: 28318726.
      View in: PubMed
    25. Bruinsma SM, Roobol MJ, Carroll P, Klotz L, Pickles T, Moore CM, Gnanapragasam VJ, Villers A, Rannikko A, Valdagni R, Frydenberg M, Kakehi Y, Filson CP, Bangma CH. Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure. Nat Rev Urol. 2017 May; 14(5):312-322. PMID: 28290462.
      View in: PubMed
    26. Chan B, Reeve E, Matthews S, Carroll P, Long JC, Held F, Latt M, Naganathan V, Caplan GA, Hilmer SN. Medicine information exchange networks among healthcare professionals and prescribing in geriatric medicine wards. Br J Clin Pharmacol. 2017 Jun; 83(6):1185-1196. PMID: 28009444.
      View in: PubMed
    27. Leapman MS, Cowan JE, Simko J, Roberge G, Stohr BA, Carroll P, Cooperberg MR. Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. Eur Urol. 2017 05; 71(5):750-759. PMID: 27940155.
      View in: PubMed
    28. Emami NC, Leong L, Wan E, Van Blarigan EL, Cooperberg MR, Tenggara I, Carroll P, Chan JM, Witte JS, Simko JP. Tissue Sources for Accurate Measurement of Germline DNA Genotypes in Prostate Cancer Patients Treated With Radical Prostatectomy. Prostate. 2017 Mar; 77(4):425-434. PMID: 27900799.
      View in: PubMed
    29. Lin DW, Newcomb LF, Brown MD, Sjoberg DD, Dong Y, Brooks JD, Carroll P, Cooperberg M, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. Eur Urol. 2017 Sep; 72(3):448-454. PMID: 27889277.
      View in: PubMed
    30. Eminaga O, Wei W, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll P, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L, Brooks JD. MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. PLoS One. 2016; 11(11):e0165236. PMID: 27846218.
      View in: PubMed
    31. McKenney JK, Wei W, Hawley S, Auman H, Newcomb LF, Boyer HD, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Tretiakova MS, Vakar-Lopez F, Carroll P, Cooperberg MR, Gleave ME, Lance RS, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD. Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. Am J Surg Pathol. 2016 Nov; 40(11):1439-1456. PMID: 27635949.
      View in: PubMed
    32. Macleod LC, Ellis WJ, Newcomb LF, Zheng Y, Brooks JD, Carroll P, Gleave ME, Lance RS, Nelson PS, Thompson IM, Wagner AA, Wei JT, Lin DW. Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. J Urol. 2017 Apr; 197(4):1026-1033. PMID: 27810448.
      View in: PubMed
    33. Leapman MS, Carroll P. What is the best way not to treat prostate cancer? Urol Oncol. 2017 02; 35(2):42-50. PMID: 27746147.
      View in: PubMed
    34. Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll P, Cooperberg MR, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Den RB, Nguyen PL, Feng FY. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol. 2016 Nov; 17(11):1612-1620. PMID: 27743920.
      View in: PubMed
    35. Villa S, Kendel F, Venderbos L, Rancati T, Bangma C, Carroll P, Denis L, Klotz L, Korfage IJ, Lane AJ, Magnani T, Mastris K, Rannikko A, Roobol M, Trock B, Van den Bergh R, Van Poppel H, Valdagni R, Bellardita L. Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force. Eur Urol. 2017 02; 71(2):274-280. PMID: 27720532.
      View in: PubMed
    36. Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M, Carroll P. Correction: Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes. PLoS One. 2016; 11(10):e0164558. PMID: 27711167.
      View in: PubMed
    37. Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll P, Small EJ, Fong L. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res. 2016 11; 4(11):948-958. PMID: 27688020.
      View in: PubMed
    38. Nguyen HG, Punnen S, Cowan JE, Leapman M, Cary C, Welty C, Weinberg V, Cooperberg MR, Meng MV, Greene KL, Garcia M, Carroll P. A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control after Robotic Assisted Radical Prostatectomy. J Urol. 2017 Feb; 197(2):369-375. PMID: 27693447.
      View in: PubMed
    39. Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll P, Small EJ, Evans MJ. 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. J Nucl Med. 2017 Jan; 58(1):81-84. PMID: 27660139.
      View in: PubMed
    40. Tran GN, Leapman MS, Nguyen HG, Cowan JE, Shinohara K, Westphalen AC, Carroll P. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance. Eur Urol. 2017 Aug; 72(2):275-281. PMID: 27595378.
      View in: PubMed
    41. Choi JY, Yang J, Noworolski SM, Behr S, Chang AJ, Simko JP, Nguyen HG, Carroll P, Kurhanewicz J, Seo Y. 18F Fluorocholine Dynamic Time-of-Flight PET/MR Imaging in Patients with Newly Diagnosed Intermediate- to High-Risk Prostate Cancer: Initial Clinical-Pathologic Comparisons. Radiology. 2017 Feb; 282(2):429-436. PMID: 27513849.
      View in: PubMed
    42. Leapman MS, Ameli N, Shinohara K, Nguyen HG, Meng MV, Cooperberg MR, Carroll P. Validity of the Cancer of the Prostate Risk Assessment Score Derived From Targeted Biopsy: Modeling Evidence From Ultrasound Lesion-Directed Biopsy. Clin Genitourin Cancer. 2017 02; 15(1):93-99. PMID: 27522449.
      View in: PubMed
    43. Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, Pettaway CA, Shore ND, Arangua P, Hoenemeyer J, Leveridge M, Leapman M, Pinto P, Thompson IM, Carroll P, Eastham J, Gomella L, Klein EA. An Approach Using PSA Levels of 1.5?ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology. 2016 Oct; 96:116-120. PMID: 27450937.
      View in: PubMed
    44. McKiernan J, Donovan MJ, O'Neill V, Bentink S, Noerholm M, Belzer S, Skog J, Kattan MW, Partin A, Andriole G, Brown G, Wei JT, Thompson IM, Carroll P. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncol. 2016 Jul 01; 2(7):882-9. PMID: 27032035.
      View in: PubMed
    45. Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll P, Cooperberg MR. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. J Urol. 2016 Nov; 196(5):1408-1414. PMID: 27352635.
      View in: PubMed
    46. Moore CM, Giganti F, Albertsen P, Allen C, Bangma C, Briganti A, Carroll P, Haider M, Kasivisvanathan V, Kirkham A, Klotz L, Ouzzane A, Padhani AR, Panebianco V, Pinto P, Puech P, Rannikko A, Renard-Penna R, Touijer K, Turkbey B, van Poppel H, Valdagni R, Walz J, Schoots I. Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force. Eur Urol. 2017 04; 71(4):648-655. PMID: 27349615.
      View in: PubMed
    47. Brooks JD, Wei W, Pollack JR, West RB, Shin JH, Sunwoo JB, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll P, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L. Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort. Prostate. 2016 Nov; 76(15):1409-19. PMID: 27325561.
      View in: PubMed
    48. Lotan TL, Wei W, Morais CL, Hawley ST, Fazli L, Hurtado-Coll A, Troyer D, McKenney JK, Simko J, Carroll P, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD. PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. Eur Urol Focus. 2016 Jun; 2(2):180-188. PMID: 27617307.
      View in: PubMed
    49. Lotan TL, Wei W, Ludkovski O, Morais CL, Guedes LB, Jamaspishvili T, Lopez K, Hawley ST, Feng Z, Fazli L, Hurtado-Coll A, McKenney JK, Simko J, Carroll P, Gleave M, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Lance R, Troyer D, Squire JA. Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. Mod Pathol. 2016 08; 29(8):904-14. PMID: 27174589.
      View in: PubMed
    50. Leapman MS, Ameli N, Cooperberg MR, Chu C, Hussein A, Shinohara K, Carroll P. Quantified Clinical Risk Change as an End Point During Prostate Cancer Active Surveillance. Eur Urol. 2017 Sep; 72(3):329-332. PMID: 27157998.
      View in: PubMed
    51. Leapman MS, Carroll P. Immediate androgen deprivation: for all or for some? Lancet Oncol. 2016 06; 17(6):683-684. PMID: 27155739.
      View in: PubMed
    52. Carroll P, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP, Kawachi MH, Kim S, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Moses KA, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenkle P, Vickers AJ, Wake R, Shead DA, Freedman-Cass DA. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. J Natl Compr Canc Netw. 2016 05; 14(5):509-19. PMID: 27160230.
      View in: PubMed
    53. Eltemamy MM, Leapman MS, Cowan JE, Westphalen A, Shinohara K, Carroll P. Serial Anatomical Prostate Ultrasound during Prostate Cancer Active Surveillance. J Urol. 2016 Sep; 196(3):727-33. PMID: 27117443.
      View in: PubMed
    54. Crehange G, Izaguirre A, Weinberg V, Hsu CC, Gottschalk AR, Hsu IC, Shinohara K, Carroll P, Roach M. Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery. Am J Clin Oncol. 2016 Apr; 39(2):167-72. PMID: 24441584.
      View in: PubMed
    55. Akaza H, Hirao Y, Kim CS, Oya M, Ozono S, Ye D, Cooperberg M, Hinotsu S, Lee JY, Zhu G, Namiki M, Horie S, Chung BH, Chen CH, Fai NC, Hakim L, Chiong E, Letran J, Umbas R, Suzuki K, Nishimura K, Ong TA, Lojanapiwat B, Wu TL, Kim WJ, Murphy D, Ogawa O, Carroll P, Naito S, Tsukamoto T. Asia prostate cancer study (A-CaP Study) launch symposium. Prostate Int. 2016 Sep; 4(3):88-96. PMID: 27689065.
      View in: PubMed
    56. Knudsen BS, Kim HL, Erho N, Shin H, Alshalalfa M, Lam LLC, Tenggara I, Chadwich K, Van Der Kwast T, Fleshner N, Davicioni E, Carroll P, Cooperberg MR, Chan JM, Simko JP. Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. J Mol Diagn. 2016 05; 18(3):395-406. PMID: 26945428; PMCID: PMC4851733 [Available on 05/01/17].
    57. Bruinsma SM, Bangma CH, Carroll P, Leapman MS, Rannikko A, Petrides N, Weerakoon M, Bokhorst LP, Roobol MJ. Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nat Rev Urol. 2016 Mar; 13(3):151-67. PMID: 26813955.
      View in: PubMed
    58. Brand TC, Zhang N, Crager MR, Maddala T, Dee A, Sesterhenn IA, Simko JP, Cooperberg MR, Srivastava S, Rosner IL, Chan JM, Febbo PG, Carroll P, Cullen J, Lawrence HJ. Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score. Urology. 2016 Mar; 89:69-75. PMID: 26723180.
      View in: PubMed
    59. Carroll P, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenke P, Vickers AJ, Wake R, Shead DA, Freedman-Cass D. NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015. J Natl Compr Canc Netw. 2015 Dec; 13(12):1534-61. PMID: 26656522.
      View in: PubMed
    60. Carlsson S, Leapman M, Carroll P, Schröder F, Albertsen PC, Ilic D, Barry M, Frosch DL, Vickers A. Who and when should we screen for prostate cancer? Interviews with key opinion leaders. BMC Med. 2015 Nov 27; 13:288. PMID: 26612204; PMCID: PMC4662021.
    61. Nordström T, Van Blarigan EL, Ngo V, Roy R, Weinberg V, Song X, Simko J, Carroll P, Chan JM, Paris PL. Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer. Prostate. 2016 Mar; 76(4):339-48. PMID: 26585352.
      View in: PubMed
    62. Hsieh AC, Nguyen HG, Wen L, Edlind MP, Carroll P, Kim W, Ruggero D. Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors. Sci Signal. 2015 Nov 17; 8(403):ra116. PMID: 26577921; PMCID: PMC4739654.
    63. Cooperberg MR, Carroll P. Treatment Trends for Prostate Cancer--Reply. JAMA. 2015 Nov 10; 314(18):1977-8. PMID: 26547474.
      View in: PubMed
    64. Leapman MS, Carroll P. New Genetic Markers for Prostate Cancer. Urol Clin North Am. 2016 Feb; 43(1):7-15. PMID: 26614025.
      View in: PubMed
    65. Sanford T, McCulloch CE, Callcut RA, Carroll P, Breyer BN. Bicycle Trauma Injuries and Hospital Admissions in the United States, 1998-2013. JAMA. 2015 Sep 01; 314(9):947-9. PMID: 26325564; PMCID: PMC4896174.
    66. Newcomb LF, Thompson IM, Boyer HD, Brooks JD, Carroll P, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol. 2016 Feb; 195(2):313-20. PMID: 26327354; PMCID: PMC4970462.
    67. Brooks JD, Wei W, Hawley S, Auman H, Newcomb L, Boyer H, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Carroll P, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, McKenney JK. Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. PLoS One. 2015; 10(7):e0132343. PMID: 26172920; PMCID: PMC4501723.
    68. Cooperberg MR, Carroll P. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. JAMA. 2015 Jul 07; 314(1):80-2. PMID: 26151271.
      View in: PubMed
    69. Filippou P, Welty CJ, Cowan JE, Perez N, Shinohara K, Carroll P. Immediate versus delayed radical prostatectomy: updated outcomes following active surveillance of prostate cancer. Eur Urol. 2015 Sep; 68(3):458-63. PMID: 26138041.
      View in: PubMed
    70. Dall'Era M, Carroll P. What is the Optimal Way to Select Candidates for Active Surveillance of Prostate Cancer? J Urol. 2015 Sep; 194(3):615-6. PMID: 26079332.
      View in: PubMed
    71. Hilmer SN, Seale JP, Carroll P. A comparison of medical and pharmacy students' knowledge and skills of pharmacology and pharmacotherapy. Br J Clin Pharmacol. 2015 Jun; 79(6):1028-9. PMID: 25425109; PMCID: PMC4456135.
    72. Hsu CC, Paciorek AT, Cooperberg MR, Roach M, Hsu IC, Carroll P. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter? BJU Int. 2015 Nov; 116(5):713-20. PMID: 25600860.
      View in: PubMed
    73. Cooperberg MR, Hinotsu S, Namiki M, Carroll P, Akaza H. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer. BJU Int. 2016 Jan; 117(1):102-9. PMID: 25238114.
      View in: PubMed
    74. Jalloh M, Leapman MS, Cowan JE, Shinohara K, Greene KL, Roach M, Chang AJ, Chan JM, Simko JP, Carroll P. Patterns of Local Failure following Radiation Therapy for Prostate Cancer. J Urol. 2015 Oct; 194(4):977-82. PMID: 25983194.
      View in: PubMed
    75. Troyer DA, Jamaspishvili T, Wei W, Feng Z, Good J, Hawley S, Fazli L, McKenney JK, Simko J, Hurtado-Coll A, Carroll P, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Squire JA. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate. 2015 Aug 01; 75(11):1206-15. PMID: 25939393; PMCID: PMC4475421.
    76. Ankerst DP, Xia J, Thompson IM, Hoefler J, Newcomb LF, Brooks JD, Carroll P, Ellis WJ, Gleave ME, Lance RS, Nelson PS, Wagner AA, Wei JT, Etzioni R, Lin DW. Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. Eur Urol. 2015 Dec; 68(6):1083-8. PMID: 25819722; PMCID: PMC4583313 [Available on 12/01/16].
    77. Hampson LA, Cowan JE, Zhao S, Carroll P, Cooperberg MR. Impact of age on quality-of-life outcomes after treatment for localized prostate cancer. Eur Urol. 2015 Sep; 68(3):480-6. PMID: 25656807.
      View in: PubMed
    78. Hussein AA, Punnen S, Zhao S, Cowan JE, Leapman M, Tran TC, Washington SL, Truesdale MD, Carroll P, Cooperberg MR. Current Use of Imaging after Primary Treatment of Prostate Cancer. J Urol. 2015 Jul; 194(1):98-104. PMID: 25640648.
      View in: PubMed
    79. Bangma CH, Valdagni R, Carroll P, van Poppel H, Klotz L, Hugosson J. Active surveillance for low-risk prostate cancer: developments to date. Eur Urol. 2015 Apr; 67(4):646-8. PMID: 25435266.
      View in: PubMed
    80. Xia J, Trock BJ, Gulati R, Mallinger L, Cooperberg MR, Carroll P, Carter HB, Etzioni R. Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics. Clin Cancer Res. 2014 Oct 15; 20(20):5302-10. PMID: 25320374; PMCID: PMC4203422.
    81. Gerstenberger JP, Bauer SR, Van Blarigan EL, Sosa E, Song X, Witte JS, Carroll P, Chan JM. Selenoprotein and antioxidant genes and the risk of high-grade prostate cancer and prostate cancer recurrence. Prostate. 2015 Jan; 75(1):60-9. PMID: 25284284; PMCID: PMC4257852.
    82. Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, Chan JM, Meng MV, Simko JP, Cooperberg MR, Carroll P. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol. 2015 Mar; 193(3):807-11. PMID: 25261803.
      View in: PubMed
    83. Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, Small EJ. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014 Nov; 106(11). PMID: 25255802; PMCID: PMC4241888.
    84. Punnen S, Cowan JE, Chan JM, Carroll P, Cooperberg MR. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Eur Urol. 2015 Oct; 68(4):600-8. PMID: 25242555.
      View in: PubMed
    85. Carroll P, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014 Sep; 12(9):1211-9; quiz 1219. PMID: 25190691.
      View in: PubMed
    86. Klein EA, Cooperberg MR, Carroll P. Reply to Yuri Tolkach, Markus Kuczyk, Florian Imkamp's letter to the editor re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur urol 2014;66:550-60. Eur Urol. 2014 Dec; 66(6):e117-8. PMID: 25150174.
      View in: PubMed
    87. Akaza H, Kim CS, Carroll P, Choi IY, Chung BH, Cooperberg MR, Hirao Y, Hinotsu S, Horie S, Lee JY, Namiki M, Ng CF, Onozawa M, Ozono S, Ueno S, Umbas R, Ye D, Zhu G. Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management. Prostate Int. 2014; 2(2):50-69. PMID: 26153555; PMCID: PMC4099396.
    88. Wang SY, Shiboski S, Belair CD, Cooperberg MR, Simko JP, Stoppler H, Cowan J, Carroll P, Blelloch R. miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance. PLoS One. 2014; 9(6):e98597. PMID: 24893170; PMCID: PMC4043973.
    89. Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll P. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014 Sep; 66(3):550-60. PMID: 24836057.
      View in: PubMed
    90. Greene KL, Punnen S, Carroll P. Evolution and immediate future of US screening guidelines. Urol Clin North Am. 2014 May; 41(2):229-35. PMID: 24725485.
      View in: PubMed
    91. Welty CJ, Cooperberg MR, Carroll P. Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer. Curr Opin Urol. 2014 May; 24(3):288-92. PMID: 24614347.
      View in: PubMed
    92. Carroll P, Vickers AJ. Point/Counterpoint: early detection of prostate cancer: do the benefits outweigh the consequences? J Natl Compr Canc Netw. 2014 May; 12(5 Suppl):768-71. PMID: 24853213.
      View in: PubMed
    93. Jalloh M, Myers F, Cowan JE, Carroll P, Cooperberg MR. Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics. Eur Urol. 2015 Mar; 67(3):451-7. PMID: 24746973.
      View in: PubMed
    94. Jarow JP, Thompson IM, Kluetz PG, Baxley J, Sridhara R, Scardino P, Carroll P, Albertsen P, Carter HB, Brawley O, Sartor O, Sandler H, Kiefert JJ, Morton RA. Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshop. Urology. 2014 May; 83(5):975-8. PMID: 24661332.
      View in: PubMed
    95. Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M, Carroll P. Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes. PLoS One. 2014; 9(3):e89754. PMID: 24594774; PMCID: PMC3940667.
    96. Bennett A, Gnjidic D, Gillett M, Carroll P, Matthews S, Johnell K, Fastbom J, Hilmer S. Prevalence and impact of fall-risk-increasing drugs, polypharmacy, and drug-drug interactions in robust versus frail hospitalised falls patients: a prospective cohort study. Drugs Aging. 2014 Mar; 31(3):225-32. PMID: 24452921.
      View in: PubMed
    97. Vickers AJ, Thompson IM, Klein E, Carroll P, Scardino PT. A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer. Urology. 2014 Mar; 83(3):592-6. PMID: 24581521.
      View in: PubMed
    98. Welty CJ, Carroll P. The ongoing need for improved risk stratification and monitoring for those on active surveillance for early stage prostate cancer. Eur Urol. 2014 Jun; 65(6):1032-3. PMID: 24636678.
      View in: PubMed
    99. Brajtbord JS, Punnen S, Cowan JE, Welty CJ, Carroll P. Age and baseline quality of life at radical prostatectomy--who has the most to lose? J Urol. 2014 Aug; 192(2):396-401. PMID: 24582539.
      View in: PubMed
    100. Wang SY, Cowan JE, Cary KC, Chan JM, Carroll P, Cooperberg MR. Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. BJU Int. 2014 Dec; 114(6b):E18-E24. PMID: 24712895.
      View in: PubMed
    101. Johnston C, Hilmer SN, McLachlan AJ, Matthews ST, Carroll P, Kirkpatrick CM. The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration. Eur J Clin Pharmacol. 2014 May; 70(5):549-55. PMID: 24522409.
      View in: PubMed
    102. Magbanua MJ, Richman EL, Sosa EV, Jones LW, Simko J, Shinohara K, Haqq CM, Carroll P, Chan JM. Physical activity and prostate gene expression in men with low-risk prostate cancer. Cancer Causes Control. 2014 Apr; 25(4):515-23. PMID: 24504435; PMCID: PMC3990413.
    103. Anwar M, Westphalen AC, Jung AJ, Noworolski SM, Simko JP, Kurhanewicz J, Roach M, Carroll P, Coakley FV. Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: quantitative analysis of imaging contour compared to whole-mount histopathology. Radiother Oncol. 2014 Feb; 110(2):303-8. PMID: 24444524.
      View in: PubMed
    104. Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014 Jun; 65(6):1046-55. PMID: 24439788; PMCID: PMC4113338.
    105. Sanford MT, Greene KL, Carroll P. The argument for palliative care in prostate cancer. Transl Androl Urol. 2013 Dec; 2(4):278-80. PMID: 26816740; PMCID: PMC4708113.
    106. Glass AS, Hilton JF, Cowan JE, Washington SL, Carroll P. Serial prostate biopsy and risk of lower urinary tract symptoms: results from a large, single-institution active surveillance cohort. Urology. 2014 Jan; 83(1):33-8. PMID: 24246319.
      View in: PubMed
    107. Jung AJ, Westphalen AC, Kurhanewicz J, Wang ZJ, Carroll P, Simko JP, Coakley FV. Clinical utility of endorectal MRI-guided prostate biopsy: preliminary experience. J Magn Reson Imaging. 2014 Aug; 40(2):314-23. PMID: 24924999; PMCID: PMC4059791.
    108. Cary KC, Singla N, Cowan JE, Carroll P, Cooperberg MR. Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer: analysis from the CaPSURE™ registry. J Urol. 2014 Apr; 191(4):964-70. PMID: 24184370.
      View in: PubMed
    109. Cary KC, Paciorek A, Fuldeore MJ, Carroll P, Cooperberg MR. Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy: an analysis from the CaPSURE registry. Cancer. 2014 Feb 15; 120(4):507-12. PMID: 24496867.
      View in: PubMed
    110. Starobinets O, Guo R, Simko JP, Kuchinsky K, Kurhanewicz J, Carroll P, Greene KL, Noworolski SM. Semiautomatic registration of digital histopathology images to in vivo MR images in molded and unmolded prostates. J Magn Reson Imaging. 2014 May; 39(5):1223-9. PMID: 24136783; PMCID: PMC3984354.
    111. Tomaszewski JJ, Richman EL, Sadetsky N, O'Keefe DS, Carroll P, Davies BJ, Chan JM. Impact of folate intake on prostate cancer recurrence following definitive therapy: data from CaPSURE™. J Urol. 2014 Apr; 191(4):971-6. PMID: 24095905.
      View in: PubMed
    112. Ornish D, Lin J, Chan JM, Epel E, Kemp C, Weidner G, Marlin R, Frenda SJ, Magbanua MJM, Daubenmier J, Estay I, Hills NK, Chainani-Wu N, Carroll P, Blackburn EH. Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. Lancet Oncol. 2013 Oct; 14(11):1112-1120. PMID: 24051140.
      View in: PubMed
    113. Cary KC, Cowan JE, Sanford M, Shinohara K, Perez N, Chan JM, Meng MV, Carroll P. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies. Eur Urol. 2014 Aug; 66(2):337-42. PMID: 24035632.
      View in: PubMed
    114. Bauer SR, Richman EL, Sosa E, Weinberg V, Song X, Witte JS, Carroll P, Chan JM. Antioxidant and vitamin E transport genes and risk of high-grade prostate cancer and prostate cancer recurrence. Prostate. 2013 Dec; 73(16):1786-95. PMID: 24038157.
      View in: PubMed
    115. Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S, van Poppel H, Roach M, Stephenson A, Wiegel T, Zelefsky MJ. Early salvage radiotherapy following radical prostatectomy. Eur Urol. 2014 Jun; 65(6):1034-43. PMID: 23972524.
      View in: PubMed
    116. Punnen S, Clint Cary K, Glass AS, Cowan JE, Carroll P. Autologous retro-pubic urethral sling: a novel, quick, intra-operative technique to improve continence after robotic-assisted radical prostatectomy. J Robot Surg. 2014 Jun; 8(2):99-104. PMID: 27637518.
      View in: PubMed
    117. Broering JM, Paciorek A, Carroll P, Wilson LS, Litwin MS, Miaskowski C. Measurement equivalence using a mixed-mode approach to administer health-related quality of life instruments. Qual Life Res. 2014 Mar; 23(2):495-508. PMID: 23943258.
      View in: PubMed
    118. Cooperberg MR, Cowan JE, Carroll P. Reply to A. Azad et al. J Clin Oncol. 2013 Sep 10; 31(26):3296-7. PMID: 23943835.
      View in: PubMed
    119. Cary KC, Carroll P. Editorial comment. J Urol. 2013 Oct; 190(4):1223. PMID: 23856519.
      View in: PubMed
    120. Punnen S, Cowan JE, Dunn LB, Shumay DM, Carroll P, Cooperberg MR. A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU Int. 2013 Jul; 112(2):E67-75. PMID: 23795800.
      View in: PubMed
    121. Akaza H, Hinotsu S, Cooperberg MR, Chung BH, Youl Lee J, Umbas R, Tsukamoto T, Namiki M, Carroll P. Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes. Jpn J Clin Oncol. 2013 Jul; 43(7):756-66. PMID: 23723314.
      View in: PubMed
    122. Glass AS, Cowan JE, Fuldeore MJ, Cooperberg MR, Carroll P, Kenfield SA, Greene KL. Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era. Urology. 2013 Jul; 82(1):60-5. PMID: 23706257.
      View in: PubMed
    123. Chang ST, Westphalen AC, Jha P, Jung AJ, Carroll P, Kurhanewicz J, Coakley FV. Endorectal MRI and MR spectroscopic imaging of prostate cancer: developing selection criteria for MR-guided focal therapy. J Magn Reson Imaging. 2014 Mar; 39(3):519-25. PMID: 23681669; PMCID: PMC3748229.
    124. Punnen S, Freedland SJ, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Carroll P, Cooperberg MR. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Eur Urol. 2014 Jun; 65(6):1171-7. PMID: 23587869.
      View in: PubMed
    125. Odisho AY, Washington SL, Meng MV, Cowan JE, Simko JP, Carroll P. Benign prostate glandular tissue at radical prostatectomy surgical margins. Urology. 2013 Jul; 82(1):154-9. PMID: 23522995; PMCID: PMC3696410.
    126. Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll P, Feng Z, Gleave ME, Lance RS, Sanda MG, Thompson IM, Wei JT, Nelson PS. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res. 2013 May 01; 19(9):2442-50. PMID: 23515404; PMCID: PMC3674574.
    127. Punnen S, Meng MV, Cooperberg MR, Greene KL, Cowan JE, Carroll P. How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer? BJU Int. 2013 Aug; 112(4):E314-20. PMID: 23451984.
      View in: PubMed
    128. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS, Swanson GP, Stone S, Carroll P. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013 Apr 10; 31(11):1428-34. PMID: 23460710.
      View in: PubMed
    129. Harris CR, Punnen S, Carroll P. Men with low preoperative sexual function may benefit from nerve sparing radical prostatectomy. J Urol. 2013 Sep; 190(3):981-6. PMID: 23410984.
      View in: PubMed
    130. Glass AS, Carroll P. Focal therapy: a new active surveillance tool? Oncology (Williston Park). 2013 Jan 15; 27(1). PMID: 25188237.
      View in: PubMed
    131. Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M, Hernandez J, Hurtado-Coll A, Kuchinsky K, Liew J, Mendez-Meza R, Smith E, Tenggara I, Zhang X, Carroll P, Chan JM, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, Feng Z, True LD, Brooks JD. A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. Adv Anat Pathol. 2013 Jan; 20(1):39-44. PMID: 23232570; PMCID: PMC3535290.
    132. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. J Urol. 2013 Jan; 189(1 Suppl):S2-S11. PMID: 23234625.
      View in: PubMed
    133. Eastham JA, Carroll P, Pisters L, Nguyen PT, Touijer K. Salvage therapies after radiation therapy. Urol Oncol. 2012 Nov-Dec; 30(6):940-1. PMID: 23218071.
      View in: PubMed
    134. Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll P, Carter HB, Etzioni R. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res. 2012 Oct 01; 18(19):5471-8. PMID: 23008476; PMCID: PMC3604990.
    135. Resnick MJ, Guzzo TJ, Cowan JE, Knight SJ, Carroll P, Penson DF. Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int. 2013 Feb; 111(2):213-20. PMID: 22928860; PMCID: PMC3540193.
    136. Choe KS, Cowan JE, Chan JM, Carroll P, D'Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012 Oct 01; 30(28):3540-4. PMID: 22927523; PMCID: PMC3454771.
    137. Odisho AY, Berry AB, Ahmad AE, Cooperberg MR, Carroll P, Konety BR. Reply to Jai Prakash, Apul Goel and Manish Garg's Letter to the Editor re: Anobel Y. Odisho, Anna B. Berry, Ardalan E. Ahmad, Matthew R. Cooperberg, Peter R. Carroll, Badrinath R. Konety. Reflex ImmunoCyt Testing for the Diagnosis of Bladder Cancer in Patients with Atypical Urine Cytology. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.04.019. Eur Urol. 2012 Nov; 62(5):e88. PMID: 22921716.
      View in: PubMed
    138. Hilton JF, Blaschko SD, Whitson JM, Cowan JE, Carroll P. The impact of serial prostate biopsies on sexual function in men on active surveillance for prostate cancer. J Urol. 2012 Oct; 188(4):1252-8. PMID: 22902015.
      View in: PubMed
    139. Yang G, Villalta JD, Weiss DA, Carroll P, Breyer BN. Gender differences in academic productivity and academic career choice among urology residents. J Urol. 2012 Oct; 188(4):1286-90. PMID: 22902027; PMCID: PMC3552430.
    140. Bangma CH, Bul M, van der Kwast TH, Pickles T, Korfage IJ, Hoeks CM, Steyerberg EW, Jenster G, Kattan MW, Bellardita L, Carroll P, Denis LJ, Parker C, Roobol MJ, Emberton M, Klotz LH, Rannikko A, Kakehi Y, Lane JA, Schröder FH, Semjonow A, Trock BJ, Valdagni R. Active surveillance for low-risk prostate cancer. Crit Rev Oncol Hematol. 2013 Mar; 85(3):295-302. PMID: 22878262.
      View in: PubMed
    141. Glass AS, Cooperberg MR, Carroll P. Early detection of prostate cancer: more information, more clarity. Eur Urol. 2012 Nov; 62(5):753-5; discussion 755-6. PMID: 22766168.
      View in: PubMed
    142. Jung AJ, Coakley FV, Shinohara K, Carroll P, Kurhanewicz J, Cowan JE, Westphalen AC. Local staging of prostate cancer: comparative accuracy of T2-weighted endorectal MR imaging and transrectal ultrasound. Clin Imaging. 2012 Sep-Oct; 36(5):547-52. PMID: 22920360; PMCID: PMC3694423.
    143. Montorsi F, Wilson TG, Rosen RC, Ahlering TE, Artibani W, Carroll P, Costello A, Eastham JA, Ficarra V, Guazzoni G, Menon M, Novara G, Patel VR, Stolzenburg JU, Van der Poel H, Van Poppel H, Mottrie A. Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol. 2012 Sep; 62(3):368-81. PMID: 22763081.
      View in: PubMed
    144. Dall'Era MA, Albertsen PC, Bangma C, Carroll P, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012 Dec; 62(6):976-83. PMID: 22698574.
      View in: PubMed
    145. Reese AC, Cowan JE, Brajtbord JS, Harris CR, Carroll P, Cooperberg MR. The quantitative Gleason score improves prostate cancer risk assessment. Cancer. 2012 Dec 15; 118(24):6046-54. PMID: 22674220.
      View in: PubMed
    146. Novara G, Ficarra V, Mocellin S, Ahlering TE, Carroll P, Graefen M, Guazzoni G, Menon M, Patel VR, Shariat SF, Tewari AK, Van Poppel H, Zattoni F, Montorsi F, Mottrie A, Rosen RC, Wilson TG. Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol. 2012 Sep; 62(3):382-404. PMID: 22749851.
      View in: PubMed
    147. Ficarra V, Novara G, Rosen RC, Artibani W, Carroll P, Costello A, Menon M, Montorsi F, Patel VR, Stolzenburg JU, Van der Poel H, Wilson TG, Zattoni F, Mottrie A. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol. 2012 Sep; 62(3):405-17. PMID: 22749852.
      View in: PubMed
    148. Hayes GM, Simko J, Holochwost D, Kuchinsky K, Busch R, Misell L, Murphy EJ, Carroll P, Chan J, Shinohara K, Hellerstein MK. Regional cell proliferation in microdissected human prostate specimens after heavy water labeling in vivo: correlation with prostate epithelial cells isolated from seminal fluid. Clin Cancer Res. 2012 Jun 15; 18(12):3250-60. PMID: 22553345.
      View in: PubMed
    149. Kane A, Mitchell SJ, Carroll P, Matthews S, Hilmer SN. Characteristics of older and younger patients with suspected paracetamol toxicity. Australas J Ageing. 2012 Sep; 31(3):190-3. PMID: 22950592.
      View in: PubMed
    150. Odisho AY, Berry AB, Ahmad AE, Cooperberg MR, Carroll P, Konety BR. Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology. Eur Urol. 2013 May; 63(5):936-40. PMID: 22521093; PMCID: PMC3443544.
    151. Berglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll P, Canby-Hagino ED, deVere White R, Hemstreet GP, Crawford ED, Thompson IM, Klein EA. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology. 2012 Mar; 79(3):633-7. PMID: 22386416; PMCID: PMC3839235.
    152. Aaronson DS, Odisho AY, Hills N, Cress R, Carroll P, Dudley RA, Cooperberg MR. Proton beam therapy and treatment for localized prostate cancer: if you build it, they will come. Arch Intern Med. 2012 Feb 13; 172(3):280-3. PMID: 22332166.
      View in: PubMed
    153. Arrayeh E, Westphalen AC, Kurhanewicz J, Roach M, Jung AJ, Carroll P, Coakley FV. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):e787-93. PMID: 22331003; PMCID: PMC3285390.
    154. Akaza H, Carroll P, Cooperberg MR, Hinotsu S. Fifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management. Jpn J Clin Oncol. 2012 Mar; 42(3):226-36. PMID: 22217576.
      View in: PubMed
    155. Cooperberg MR, Odisho AY, Carroll P. Outcomes for radical prostatectomy: is it the singer, the song, or both? J Clin Oncol. 2012 Feb 10; 30(5):476-8. PMID: 22215744.
      View in: PubMed
    156. Messing EM, Albertsen P, Andriole GL, Carroll P, Klein EA. The Society of Urologic Oncology's reply to the US Preventative Services Task Force's recommendation on PSA testing. Urol Oncol. 2012 Jan-Feb; 30(1):117-9. PMID: 22243597.
      View in: PubMed
    157. Muglia VF, Westphalen AC, Wang ZJ, Kurhanewicz J, Carroll P, Coakley FV. Endorectal MRI of prostate cancer: incremental prognostic importance of gross locally advanced disease. AJR Am J Roentgenol. 2011 Dec; 197(6):1369-74. PMID: 22109291; PMCID: PMC3703946.
    158. Washington SL, Bonham M, Whitson JM, Cowan JE, Carroll P. Transrectal ultrasonography-guided biopsy does not reliably identify dominant cancer location in men with low-risk prostate cancer. BJU Int. 2012 Jul; 110(1):50-5. PMID: 22077660.
      View in: PubMed
    159. Reese AC, Fradet V, Whitson JM, Davis CB, Carroll P. Poor agreement of prostate specific antigen doubling times calculated using ultrasensitive versus standard prostate specific antigen values: important impact on risk assessment. J Urol. 2011 Dec; 186(6):2228-32. PMID: 22014796.
      View in: PubMed
    160. Punnen S, Cooperberg MR, Sadetsky N, Carroll P. Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores? BJU Int. 2012 May; 109(10):1520-4. PMID: 21999368; PMCID: PMC3288727.
    161. Porten SP, Whitson JM, Cowan JE, Perez N, Shinohara K, Carroll P. Changes in cancer volume in serial biopsies of men on active surveillance for early stage prostate cancer. J Urol. 2011 Nov; 186(5):1825-9. PMID: 21944082.
      View in: PubMed
    162. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll P, Sanda MG. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011 Sep 21; 306(11):1205-14. PMID: 21934053; PMCID: PMC3831607.
    163. Magbanua MJ, Roy R, Sosa EV, Weinberg V, Federman S, Mattie MD, Hughes-Fulford M, Simko J, Shinohara K, Haqq CM, Carroll P, Chan JM. Gene expression and biological pathways in tissue of men with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation. PLoS One. 2011; 6(9):e24004. PMID: 21912659; PMCID: PMC3164676.
    164. Richman EL, Carroll P, Chan JM. Vegetable and fruit intake after diagnosis and risk of prostate cancer progression. Int J Cancer. 2012 Jul 01; 131(1):201-10. PMID: 21823116; PMCID: PMC3310254.
    165. Punnen S, Cooperberg MR, Sadetsky N, Carroll P. Androgen deprivation therapy and cardiovascular risk. J Clin Oncol. 2011 Sep 10; 29(26):3510-6. PMID: 21844498; PMCID: PMC3179251.
    166. Cooperberg MR, Carroll P, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol. 2011 Sep 20; 29(27):3669-76. PMID: 21825257.
      View in: PubMed
    167. McKenney JK, Simko J, Bonham M, True LD, Troyer D, Hawley S, Newcomb LF, Fazli L, Kunju LP, Nicolas MM, Vakar-Lopez F, Zhang X, Carroll P, Brooks JD. The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study. J Urol. 2011 Aug; 186(2):465-9. PMID: 21679996.
      View in: PubMed
    168. Cooperberg MR, Mallin K, Kane CJ, Carroll P. Treatment trends for stage I renal cell carcinoma. J Urol. 2011 Aug; 186(2):394-9. PMID: 21679982.
      View in: PubMed
    169. Cooperberg MR, Hilton JF, Carroll P. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011 Nov 15; 117(22):5039-46. PMID: 21647869; PMCID: PMC3170662.
    170. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll P. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol. 2011 Jul 10; 29(20):2795-800. PMID: 21632511.
      View in: PubMed
    171. Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll P, Chan JM. Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res. 2011 Jun 01; 71(11):3889-95. PMID: 21610110; PMCID: PMC3107352.
    172. Ploussard G, Epstein JI, Montironi R, Carroll P, Wirth M, Grimm MO, Bjartell AS, Montorsi F, Freedland SJ, Erbersdobler A, van der Kwast TH. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol. 2011 Aug; 60(2):291-303. PMID: 21601982.
      View in: PubMed
    173. Whitson JM, Porten SP, Cowan JE, Simko JP, Cooperberg MR, Carroll P. Factors associated with downgrading in patients with high grade prostate cancer. Urol Oncol. 2013 May; 31(4):442-7. PMID: 21478037.
      View in: PubMed
    174. Dall'Era MA, Cowan JE, Simko J, Shinohara K, Davies B, Konety BR, Meng MV, Perez N, Greene K, Carroll P. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Int. 2011 Apr; 107(8):1232-7. PMID: 20804478.
      View in: PubMed
    175. Carroll P, Whitson JM. Editorial comment. Urology. 2011 Apr; 77(4):984-5. PMID: 21477729.
      View in: PubMed
    176. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll P. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol. 2011 May; 185(5):1656-60. PMID: 21419438.
      View in: PubMed
    177. Mallin K, David KA, Carroll P, Milowsky MI, Nanus DM. Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). J Urol. 2011 May; 185(5):1631-6. PMID: 21419456.
      View in: PubMed
    178. Sadetsky N, Greene K, Cooperberg MR, Hubbard A, Carroll P, Satariano W. Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry. Cancer. 2011 Oct 01; 117(19):4406-13. PMID: 21412760.
      View in: PubMed
    179. Porten SP, Cooperberg MR, Konety BR, Carroll P. The example of CaPSURE: lessons learned from a national disease registry. World J Urol. 2011 Jun; 29(3):265-71. PMID: 21347810; PMCID: PMC3099175.
    180. Whitson JM, Porten SP, Carroll P. Prostate cancer: reducing overtreatment: active surveillance in low-risk disease. Nat Rev Urol. 2011 Mar; 8(3):124-5. PMID: 21304508.
      View in: PubMed
    181. Kazer MW, Bailey DE, Colberg J, Kelly WK, Carroll P. The needs for men undergoing active surveillance (AS) for prostate cancer: results of a focus group study. J Clin Nurs. 2011 Feb; 20(3-4):581-6. PMID: 21219530.
      View in: PubMed
    182. Hilmer SN, Tran K, Rubie P, Wright J, Gnjidic D, Mitchell SJ, Matthews S, Carroll P. Gentamicin pharmacokinetics in old age and frailty. Br J Clin Pharmacol. 2011 Feb; 71(2):224-31. PMID: 21219402; PMCID: PMC3040542.
    183. Yang G, Whitson JM, Breyer BN, Konety BR, Carroll P. Oncological and functional outcomes of radical cystectomy and orthotopic bladder replacement in women. Urology. 2011 Apr; 77(4):878-83. PMID: 21215428; PMCID: PMC3607667.
    184. Carroll P, Whitson JM, Cooperberg MR. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes? J Clin Oncol. 2011 Feb 01; 29(4):345-7. PMID: 21189396.
      View in: PubMed
    185. Yang G, Zaid UB, Erickson BA, Blaschko SD, Carroll P, Breyer BN. Urology resident publication output and its relationship to future academic achievement. J Urol. 2011 Feb; 185(2):642-6. PMID: 21168863; PMCID: PMC3565588.
    186. Bechis SK, Carroll P, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. 2011 Jan 10; 29(2):235-41. PMID: 21135285; PMCID: PMC3058279.
    187. Breyer BN, Davis CB, Cowan JE, Kane CJ, Carroll P. Incidence of bladder neck contracture after robot-assisted laparoscopic and open radical prostatectomy. BJU Int. 2010 Dec; 106(11):1734-8. PMID: 20438567; PMCID: PMC3565608.
    188. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll P. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol. 2011 Jan 10; 29(2):228-34. PMID: 21115873; PMCID: PMC3058278.
    189. Reese AC, Sadetsky N, Carroll P, Cooperberg MR. Inaccuracies in assignment of clinical stage for localized prostate cancer. Cancer. 2011 Jan 15; 117(2):283-9. PMID: 21210472.
      View in: PubMed
    190. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stöppler H, Simko J, Hilton JF, Carroll P, Blelloch R. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 2011 Jan 15; 71(2):550-60. PMID: 21098088; PMCID: PMC3022112.
    191. Chan JM, Weinberg V, Magbanua MJ, Sosa E, Simko J, Shinohara K, Federman S, Mattie M, Hughes-Fulford M, Haqq C, Carroll P. Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer. Cancer Causes Control. 2011 Jan; 22(1):141-50. PMID: 21103921; PMCID: PMC3002170.
    192. Cooperberg MR, Vickers AJ, Broering JM, Carroll P. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010 Nov 15; 116(22):5226-34. PMID: 20690197; PMCID: PMC2975879.
    193. Porten SP, Richardson DA, Odisho AY, McAninch JW, Carroll P, Cooperberg MR. Disproportionate presentation of high risk prostate cancer in a safety net health system. J Urol. 2010 Nov; 184(5):1931-6. PMID: 20846693.
      View in: PubMed
    194. Katz MS, Carroll P, Cowan JE, Chan JM, D'Amico AV. Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU Int. 2010 Sep; 106(5):627-32. PMID: 20151961.
      View in: PubMed
    195. Tasian GE, Cooperberg MR, Cowan JE, Keyashian K, Greene KL, Daniels NA, Carroll P, Chan JM. Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians. Urol Oncol. 2012 Mar-Apr; 30(2):155-60. PMID: 20800514.
      View in: PubMed
    196. Vickers AJ, Salz T, Basch E, Cooperberg MR, Carroll P, Tighe F, Eastham J, Rosen RC. Electronic patient self-assessment and management (SAM): a novel framework for cancer survivorship. BMC Med Inform Decis Mak. 2010 Jun 17; 10:34. PMID: 20565745; PMCID: PMC2893444.
    197. Fradet V, Kurhanewicz J, Cowan JE, Karl A, Coakley FV, Shinohara K, Carroll P. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology. 2010 Jul; 256(1):176-83. PMID: 20505068; PMCID: PMC2897693.
    198. Reese AC, Cooperberg MR, Carroll P. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease. J Urol. 2010 Jul; 184(1):114-9. PMID: 20478578.
      View in: PubMed
    199. Whitson JM, Carroll P. Active surveillance for early-stage prostate cancer: defining the triggers for intervention. J Clin Oncol. 2010 Jun 10; 28(17):2807-9. PMID: 20439633.
      View in: PubMed
    200. Walsh TJ, Schembri M, Turek PJ, Chan JM, Carroll P, Smith JF, Eisenberg ML, Van Den Eeden SK, Croughan MS. Increased risk of high-grade prostate cancer among infertile men. Cancer. 2010 May 01; 116(9):2140-7. PMID: 20309846; PMCID: PMC2893877.
    201. Odisho AY, Cooperberg MR, Fradet V, Ahmad AE, Carroll P. Urologist density and county-level urologic cancer mortality. J Clin Oncol. 2010 May 20; 28(15):2499-504. PMID: 20406931; PMCID: PMC2881728.
    202. Fang AC, Ahmad AE, Whitson JM, Ferrell LD, Carroll P, Konety BR. Effect of a minimum lymph node policy in radical cystectomy and pelvic lymphadenectomy on lymph node yields, lymph node positivity rates, lymph node density, and survivorship in patients with bladder cancer. Cancer. 2010 Apr 15; 116(8):1901-8. PMID: 20186823.
      View in: PubMed
    203. Katz MS, Efstathiou JA, D'Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll P, Zietman AL. The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int. 2010 May; 105(10):1417-22. PMID: 20346051; PMCID: PMC3090683.
    204. Le JD, Cooperberg MR, Sadetsky N, Hittelman AB, Meng MV, Cowan JE, Latini DM, Carroll P. Changes in specific domains of sexual function and sexual bother after radical prostatectomy. BJU Int. 2010 Oct; 106(7):1022-9. PMID: 20184571.
      View in: PubMed
    205. Cooperberg MR, Broering JM, Carroll P. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010 Mar 01; 28(7):1117-23. PMID: 20124165; PMCID: PMC2834465.
    206. Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll P, Carter HB, Catalona WJ, Cookson MS, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP, Howe RJ, Lange PH, Lilja H, Loughlin KR, Mohler J, Moul J, Nadler RB, Patterson SG, Presti JC, Stroup AM, Wake R, Wei JT. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw. 2010 Feb; 8(2):240-62. PMID: 20141680.
      View in: PubMed
    207. Moses KA, Paciorek AT, Penson DF, Carroll P, Master VA. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol. 2010 Feb 20; 28(6):1069-74. PMID: 20100957; PMCID: PMC2834431.
    208. Smaldone MC, Cowan JE, Carroll P, Davies BJ. Eligibility for active surveillance and pathological outcomes for men undergoing radical prostatectomy in a large, community based cohort. J Urol. 2010 Jan; 183(1):138-43. PMID: 19913808.
      View in: PubMed
    209. Doyle SM, Kahn JG, Hosang N, Carroll P. The impact of male circumcision on HIV transmission. J Urol. 2010 Jan; 183(1):21-6. PMID: 19913816.
      View in: PubMed
    210. Richman EL, Stampfer MJ, Paciorek A, Broering JM, Carroll P, Chan JM. Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression. Am J Clin Nutr. 2010 Mar; 91(3):712-21. PMID: 20042525; PMCID: PMC3132069.
    211. Santos CF, Kurhanewicz J, Tabatabai ZL, Simko JP, Keshari KR, Gbegnon A, Santos RD, Federman S, Shinohara K, Carroll P, Haqq CM, Swanson MG. Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy. NMR Biomed. 2010 May; 23(4):391-8. PMID: 20033906; PMCID: PMC2891902.
    212. Paris PL, Weinberg V, Albo G, Roy R, Burke C, Simko J, Carroll P, Collins C. A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer. Clin Cancer Res. 2010 Jan 01; 16(1):195-202. PMID: 20028763; PMCID: PMC2854027.
    213. Carroll P. Editorial comment. J Urol. 2010 Feb; 183(2):564. PMID: 20018313.
      View in: PubMed
    214. Aaronson D, Cowan J, Carroll P, Konety B. Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE. BJU Int. 2010 Apr; 105(7):951-5. PMID: 19889066.
      View in: PubMed
    215. Eisenberg ML, Cowan JE, Carroll P, Shinohara K. The adjunctive use of power Doppler imaging in the preoperative assessment of prostate cancer. BJU Int. 2010 May; 105(9):1237-41. PMID: 19888980.
      View in: PubMed
    216. Whitson JM, Berry AB, Carroll P, Konety BR. UroVysion testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer. Int Braz J Urol. 2009 Nov-Dec; 35(6):664-70; discussion 671-2. PMID: 20028572.
      View in: PubMed
    217. Lin GA, Aaronson DS, Knight SJ, Carroll P, Dudley RA. Patient decision aids for prostate cancer treatment: a systematic review of the literature. CA Cancer J Clin. 2009 Nov-Dec; 59(6):379-90. PMID: 19841280.
      View in: PubMed
    218. Abouassaly R, Paciorek A, Ryan CJ, Carroll P, Klein EA. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE. Cancer. 2009 Oct 01; 115(19):4470-6. PMID: 19637339.
      View in: PubMed
    219. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009 Nov; 182(5):2232-41. PMID: 19781717.
      View in: PubMed
    220. Bailey DE, Wallace M, Latini DM, Hegarty J, Carroll P, Klein EA, Albertsen PC. Measuring illness uncertainty in men undergoing active surveillance for prostate cancer. Appl Nurs Res. 2011 Nov; 24(4):193-9. PMID: 20974073; PMCID: PMC3070758.
    221. Newcomb LF, Brooks JD, Carroll P, Feng Z, Gleave ME, Nelson PS, Thompson IM, Lin DW. Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology. 2010 Feb; 75(2):407-13. PMID: 19758683; PMCID: PMC3827723.
    222. Sadetsky N, Hubbard A, Carroll P, Satariano W. Predictive value of serial measurements of quality of life on all-cause mortality in prostate cancer patients: data from CaPSURE (cancer of the prostate strategic urologic research endeavor) database. Qual Life Res. 2009 Oct; 18(8):1019-27. PMID: 19697155; PMCID: PMC2744792.
    223. Porten SP, Cooperberg MR, Carroll P. The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease. BJU Int. 2010 Feb; 105(4):472-5. PMID: 19681901; PMCID: PMC2821458.
    224. Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll P, Akaza H. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol. 2009 Sep 10; 27(26):4306-13. PMID: 19667269; PMCID: PMC2744272.
    225. Cooperberg MR, Carroll P. Prostate-cancer screening. N Engl J Med. 2009 Jul 09; 361(2):203; author reply 204-5. PMID: 19593852.
      View in: PubMed
    226. Cooperberg MR, Kane CJ, Cowan JE, Carroll P. Adequacy of lymphadenectomy among men undergoing robot-assisted laparoscopic radical prostatectomy. BJU Int. 2010 Jan; 105(1):88-92. PMID: 19549119.
      View in: PubMed
    227. Cooperberg MR, Broering JM, Carroll P. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009 Jun 16; 101(12):878-87. PMID: 19509351; PMCID: PMC2697208.
    228. Davies BJ, Smaldone MC, Sadetsky N, Dall'era M, Carroll P. The impact of obesity on overall and cancer specific survival in men with prostate cancer. J Urol. 2009 Jul; 182(1):112-7; discussion 117. PMID: 19447437.
      View in: PubMed
    229. Dall'Era MA, Carroll P. Outcomes and follow-up strategies for patients on active surveillance. Curr Opin Urol. 2009 May; 19(3):258-62. PMID: 19295434.
      View in: PubMed
    230. Michalski JM, Roach M, Merrick G, Anscher MS, Beyer DC, Lawton CA, Lee WR, Pollack A, Rosenthal SA, Vijayakumar S, Carroll P. ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate. Int J Radiat Oncol Biol Phys. 2009 Jul 01; 74(3):667-72. PMID: 19386445.
      View in: PubMed
    231. Eisenberg ML, Cowan JE, Davies BJ, Carroll P, Shinohara K. The importance of tumor palpability and transrectal ultrasonographic appearance in the contemporary clinical staging of prostate cancer. Urol Oncol. 2011 Mar-Apr; 29(2):171-6. PMID: 19362864.
      View in: PubMed
    232. Eisenberg ML, Davies BJ, Cooperberg MR, Cowan JE, Carroll P. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol. 2010 Apr; 57(4):622-9. PMID: 19375843; PMCID: PMC2930030.
    233. David KA, Mallin K, Milowsky MI, Ritchey J, Carroll P, Nanus DM. Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000. Cancer. 2009 Apr 01; 115(7):1435-47. PMID: 19215030.
      View in: PubMed
    234. Ross PL, Cheng I, Liu X, Cicek MS, Carroll P, Casey G, Witte JS. Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer. BMC Cancer. 2009 Feb 26; 9:69. PMID: 19245716; PMCID: PMC2657151.
    235. Dall'era MA, Hosang N, Konety B, Cowan JE, Carroll P. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease. J Urol. 2009 Apr; 181(4):1622-7; discussion 1627. PMID: 19230923.
      View in: PubMed
    236. Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll P. Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol. 2009 Apr; 181(4):1628-33; discussion 1633-4. PMID: 19233388.
      View in: PubMed
    237. Chen RC, Sadetsky N, Chen MH, Carroll P, D'Amico AV. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy. Int J Radiat Oncol Biol Phys. 2009 Sep 01; 75(1):36-9. PMID: 19233568.
      View in: PubMed
    238. Whitson J, Berry A, Carroll P, Konety B. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int. 2009 Aug; 104(3):336-9. PMID: 19220253.
      View in: PubMed
    239. Konety BR, Cooperberg MR, Carroll P. Are age-based criteria the best way to determine eligibility for prostate cancer screening? Ann Intern Med. 2009 Feb 03; 150(3):220-1; author reply 221-2. PMID: 19189916.
      View in: PubMed
    240. Breyer BN, Whitson JM, Carroll P, Konety BR. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol. 2010 Sep-Oct; 28(5):510-4. PMID: 19171491; PMCID: PMC3565601.
    241. Karl A, Carroll P, Gschwend JE, Knüchel R, Montorsi F, Stief CG, Studer UE. The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol. 2009 Apr; 55(4):826-35. PMID: 19150582.
      View in: PubMed
    242. Odisho AY, Fradet V, Cooperberg MR, Ahmad AE, Carroll P. Geographic distribution of urologists throughout the United States using a county level approach. J Urol. 2009 Feb; 181(2):760-5; discussion 765-6. PMID: 19091334.
      View in: PubMed
    243. Sartor AO, Hricak H, Wheeler TM, Coleman J, Penson DF, Carroll P, Rubin MA, Scardino PT. Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology. 2008 Dec; 72(6 Suppl):S12-24. PMID: 19095124.
      View in: PubMed
    244. Zerbib M, Zelefsky MJ, Higano CS, Carroll P. Conventional treatments of localized prostate cancer. Urology. 2008 Dec; 72(6 Suppl):S25-35. PMID: 19095125.
      View in: PubMed
    245. Marberger M, Carroll P, Zelefsky MJ, Coleman JA, Hricak H, Scardino PT, Abenhaim LL. New treatments for localized prostate cancer. Urology. 2008 Dec; 72(6 Suppl):S36-43. PMID: 19095127.
      View in: PubMed
    246. Simone NL, Singh AK, Cowan JE, Soule BP, Carroll P, Litwin MS. Pretreatment predictors of death from other causes in men with prostate cancer. J Urol. 2008 Dec; 180(6):2447-51; discussion 2451-2. PMID: 18930498.
      View in: PubMed
    247. White WM, Sadetsky N, Waters WB, Carroll P, Litwin MS. Quality of life in men with locally advanced adenocarcinoma of the prostate: an exploratory analysis using data from the CaPSURE database. J Urol. 2008 Dec; 180(6):2409-13; discussion 2414. PMID: 18930270.
      View in: PubMed
    248. Wu AK, Cooperberg MR, Sadetsky N, Carroll P. Health related quality of life in patients treated with multimodal therapy for prostate cancer. J Urol. 2008 Dec; 180(6):2415-22; discussion 2422. PMID: 18930279.
      View in: PubMed
    249. Isbarn H, Boccon-Gibod L, Carroll P, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UE. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol. 2009 Jan; 55(1):62-75. PMID: 18945543; PMCID: PMC3090670.
    250. Hong YM, Hu JC, Paciorek AT, Knight SJ, Carroll P. Impact of radical prostatectomy positive surgical margins on fear of cancer recurrence: results from CaPSURE. Urol Oncol. 2010 May-Jun; 28(3):268-73. PMID: 18848785.
      View in: PubMed
    251. Ornish D, Lin J, Daubenmier J, Weidner G, Epel E, Kemp C, Magbanua MJ, Marlin R, Yglecias L, Carroll P, Blackburn EH. Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol. 2008 Nov; 9(11):1048-57. PMID: 18799354.
      View in: PubMed
    252. Barocas DA, Cowan JE, Smith JA, Carroll P. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol. 2008 Oct; 180(4):1330-4; discussion 1334-5. PMID: 18707731.
      View in: PubMed
    253. Frattaroli J, Weidner G, Dnistrian AM, Kemp C, Daubenmier JJ, Marlin RO, Crutchfield L, Yglecias L, Carroll P, Ornish D. Clinical events in prostate cancer lifestyle trial: results from two years of follow-up. Urology. 2008 Dec; 72(6):1319-23. PMID: 18602144.
      View in: PubMed
    254. Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll P, Zektzer AS, Kurhanewicz J. Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn Reson Med. 2008 Jul; 60(1):33-40. PMID: 18581409; PMCID: PMC2643975.
    255. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll P. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer. 2008 Jul 01; 113(1):78-83. PMID: 18491376.
      View in: PubMed
    256. Ornish D, Magbanua MJ, Weidner G, Weinberg V, Kemp C, Green C, Mattie MD, Marlin R, Simko J, Shinohara K, Haqq CM, Carroll P. Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci U S A. 2008 Jun 17; 105(24):8369-74. PMID: 18559852; PMCID: PMC2430265.
    257. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll P. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008 Jun 15; 112(12):2664-70. PMID: 18433013.
      View in: PubMed
    258. Cooperberg MR, Mallin K, Ritchey J, Villalta JD, Carroll P, Kane CJ. Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004. J Urol. 2008 Jun; 179(6):2131-5. PMID: 18423754.
      View in: PubMed
    259. Arredondo SA, Downs TM, Lubeck DP, Pasta DJ, Silva SJ, Wallace KL, Carroll P. Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J Urol. 2008 May; 179(5 Suppl):S14-8. PMID: 18405740.
      View in: PubMed
    260. Cabrera AR, Coakley FV, Westphalen AC, Lu Y, Zhao S, Shinohara K, Carroll P, Kurhanewicz J. Prostate cancer: is inapparent tumor at endorectal MR and MR spectroscopic imaging a favorable prognostic finding in patients who select active surveillance? Radiology. 2008 May; 247(2):444-50. PMID: 18430877; PMCID: PMC3705558.
    261. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE, Wallace ME, Kantoff PW, Carroll P. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008 Apr 15; 112(8):1650-9. PMID: 18306379.
      View in: PubMed
    262. Cooperberg MR, Cowan J, Broering JM, Carroll P. High-risk prostate cancer in the United States, 1990-2007. World J Urol. 2008 Jun; 26(3):211-8. PMID: 18369637; PMCID: PMC2948572.
    263. Walsh TJ, Davies BJ, Croughan MS, Carroll P, Turek PJ. Racial differences among boys with testicular germ cell tumors in the United States. J Urol. 2008 May; 179(5):1961-5. PMID: 18355842.
      View in: PubMed
    264. Bellizzi KM, Latini DM, Cowan JE, DuChane J, Carroll P. Fear of recurrence, symptom burden, and health-related quality of life in men with prostate cancer. Urology. 2008 Dec; 72(6):1269-73. PMID: 18342930.
      View in: PubMed
    265. Woldrich JM, Mallin K, Ritchey J, Carroll P, Kane CJ. Sex differences in renal cell cancer presentation and survival: an analysis of the National Cancer Database, 1993-2004. J Urol. 2008 May; 179(5):1709-13; discussion 1713. PMID: 18343430.
      View in: PubMed
    266. Konety BR, Cowan JE, Carroll P. Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. J Urol. 2008 May; 179(5):1797-803; discussion 1803. PMID: 18343440.
      View in: PubMed
    267. Sadetsky N, Lubeck DP, Pasta DJ, Latini DM, DuChane J, Carroll P. Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor. BJU Int. 2008 Mar; 101(6):691-7. PMID: 18291018.
      View in: PubMed
    268. Davies BJ, Walsh TJ, Ross PL, Knight SJ, Sadetsky N, Carroll P, Kane CJ. Effect of BMI on primary treatment of prostate cancer. Urology. 2008 Aug; 72(2):406-11. PMID: 18267336.
      View in: PubMed
    269. Choueiri TK, Dreicer R, Paciorek A, Carroll P, Konety B. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol. 2008 Mar; 179(3):906-10; discussion 910. PMID: 18207194.
      View in: PubMed
    270. Lee IH, Sadetsky N, Carroll P, Sandler HM. The impact of treatment choice for localized prostate cancer on response to phosphodiesterase inhibitors. J Urol. 2008 Mar; 179(3):1072-6; discussion 1076. PMID: 18206926.
      View in: PubMed
    271. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll P. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer. 2008 Jan 15; 112(2):307-14. PMID: 18050294.
      View in: PubMed
    272. Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol. 2008 Jan; 18(1):71-7. PMID: 18090494; PMCID: PMC2804482.
    273. Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. Urology. 2008 Jan; 71(1):136-40. PMID: 18242382.
      View in: PubMed
    274. Macdonald OK, D'Amico AV, Sadetsky N, Shrieve DC, Carroll P. Predicting PSA failure following salvage radiotherapy for a rising PSA post-prostatectomy: from the CaPSURE database. Urol Oncol. 2008 May-Jun; 26(3):271-5. PMID: 18452818.
      View in: PubMed
    275. Scales CD, Moul JW, Curtis LH, Elkin EP, Hughes ME, Carroll P. Prostate cancer in the Baby Boomer generation: results from CaPSURE. Urology. 2007 Dec; 70(6):1162-7. PMID: 18158039.
      View in: PubMed
    276. Westphalen AC, Coakley FV, Qayyum A, Swanson M, Simko JP, Lu Y, Zhao S, Carroll P, Yeh BM, Kurhanewicz J. Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging. Radiology. 2008 Jan; 246(1):177-84. PMID: 18024434.
      View in: PubMed
    277. Shah JB, McKiernan JM, Elkin EP, Carroll P, Meng MV. Prostate biopsy patterns in the CaPSURE database: evolution with time and impact on outcome after prostatectomy. J Urol. 2008 Jan; 179(1):136-40. PMID: 17997437.
      View in: PubMed
    278. Eggener SE, Scardino PT, Carroll P, Zelefsky MJ, Sartor O, Hricak H, Wheeler TM, Fine SW, Trachtenberg J, Rubin MA, Ohori M, Kuroiwa K, Rossignol M, Abenhaim L. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007 Dec; 178(6):2260-7. PMID: 17936815.
      View in: PubMed
    279. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll P. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007 Oct 17; 99(20):1516-24. PMID: 17925537.
      View in: PubMed
    280. Walsh TJ, Dall'Era MA, Croughan MS, Carroll P, Turek PJ. Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer. J Urol. 2007 Oct; 178(4 Pt 1):1440-6; discussion 1446. PMID: 17706709.
      View in: PubMed
    281. Alexander BM, Chen MH, Carroll P, D'Amico AV. Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response. Urology. 2007 Aug; 70(2):320-3. PMID: 17826497.
      View in: PubMed
    282. Kawachi MH, Bahnson RR, Barry M, Carroll P, Carter HB, Catalona WJ, Epstein JI, Etzioni RB, Hemstreet GP, Howe RJ, Kopin JD, Lange PH, Lilja H, Mohler J, Moul J, Nadler RB, Patterson S, Pollack A, Presti JC, Stroup AM, Urban DA, Wake R, Wei JT. Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Aug; 5(7):714-36. PMID: 17692177.
      View in: PubMed
    283. Kantoff PW, Beer TM, D'Amico AV, Dipaola RS, Eisenberger MA, Hussain MH, Kelly WK, Mathew P, Morris MJ, Ryan CJ, Sandler HM, Thompson IM, Carroll P. Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference. J Urol. 2007 Sep; 178(3 Pt 2):S5-8; quiz S4. PMID: 17644118.
      View in: PubMed
    284. Cooperberg MR, Broering JM, Kantoff PW, Carroll P. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007 Sep; 178(3 Pt 2):S14-9. PMID: 17644125; PMCID: PMC2987559.
    285. Hart SL, Latini DM, Cowan JE, Carroll P. Fear of recurrence, treatment satisfaction, and quality of life after radical prostatectomy for prostate cancer. Support Care Cancer. 2008 Feb; 16(2):161-9. PMID: 17638026.
      View in: PubMed
    286. Latini DM, Hart SL, Knight SJ, Cowan JE, Ross PL, Duchane J, Carroll P. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol. 2007 Sep; 178(3 Pt 1):826-31; discussion 831-2. PMID: 17632144.
      View in: PubMed
    287. Macdonald OK, D'Amico AV, Sadetsky N, Shrieve DC, Carroll P. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database. Urology. 2007 Jul; 70(1):106-10. PMID: 17656218.
      View in: PubMed
    288. Ryan CJ, Elkin EP, Cowan J, Carroll P. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE. Cancer. 2007 Jul 01; 110(1):81-6. PMID: 17516446.
      View in: PubMed
    289. Elliott SP, Meng MV, Elkin EP, McAninch JW, Duchane J, Carroll P. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. J Urol. 2007 Aug; 178(2):529-34; discussion 534. PMID: 17570425.
      View in: PubMed
    290. David KA, Milowsky MI, Ritchey J, Carroll P, Nanus DM. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol. 2007 Aug; 178(2):451-4. PMID: 17561135.
      View in: PubMed
    291. Knight SJ, Latini DM, Hart SL, Sadetsky N, Kane CJ, DuChane J, Carroll P. Education predicts quality of life among men with prostate cancer cared for in the Department of Veterans Affairs: a longitudinal quality of life analysis from CaPSURE. Cancer. 2007 May 01; 109(9):1769-76. PMID: 17380491.
      View in: PubMed
    292. Dall'Era M, Carroll P. Prostate cancer--more information and more questions. J Urol. 2007 May; 177(5):1607-8. PMID: 17437768.
      View in: PubMed
    293. Konety BR, Sadetsky N, Carroll P. Recovery of urinary continence following radical prostatectomy: the impact of prostate volume--analysis of data from the CaPSURE Database. J Urol. 2007 Apr; 177(4):1423-5; discussion 1425-6. PMID: 17382745.
      View in: PubMed
    294. Lee WR, Sharkey J, Cowan JE, DuChane J, Carroll P. Prostate brachytherapy: a descriptive analysis from CaPSURE. Brachytherapy. 2007 Apr-Jun; 6(2):123-8. PMID: 17434105.
      View in: PubMed
    295. D'Amico AV, McLeod DG, Carroll P, Cullen J, Chen MH. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality. Cancer. 2007 Apr 01; 109(7):1290-5. PMID: 17315162.
      View in: PubMed
    296. Boorjian S, Cowan JE, Konety BR, DuChane J, Tewari A, Carroll P, Kane CJ. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol. 2007 Mar; 177(3):883-7; discussion 887-8. PMID: 17296367.
      View in: PubMed
    297. Berglund RK, Sadetsky N, DuChane J, Carroll P, Klein EA. Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE. J Urol. 2007 Feb; 177(2):526-29; discussion 529-30. PMID: 17222625.
      View in: PubMed
    298. Wilson LS, Tesoro R, Elkin EP, Sadetsky N, Broering JM, Latini DM, DuChane J, Mody RR, Carroll P. Cumulative cost pattern comparison of prostate cancer treatments. Cancer. 2007 Feb 01; 109(3):518-27. PMID: 17186528.
      View in: PubMed
    299. Konety BR, Allareddy V, Carroll P. Factors affecting outcomes after radical cystectomy in African Americans. Cancer. 2007 Feb 01; 109(3):542-8. PMID: 17200961.
      View in: PubMed
    300. Coakley FV, Chen I, Qayyum A, Westphalen AC, Carroll P, Hricak H, Chen MH, Kurhanewicz J. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging. BJU Int. 2007 Jan; 99(1):41-5. PMID: 17227490.
      View in: PubMed
    301. Arredondo SA, Latini DM, Sadetsky N, Kawakami J, Pasta DJ, DuChane J, Carroll P. Quality of life for men receiving a second treatment for prostate cancer. J Urol. 2007 Jan; 177(1):273-8; discussion 278-9. PMID: 17162062.
      View in: PubMed
    302. Dewell A, Weidner G, Sumner MD, Barnard RJ, Marlin RO, Daubenmier JJ, Chi C, Carroll P, Ornish D. Relationship of dietary protein and soy isoflavones to serum IGF-1 and IGF binding proteins in the Prostate Cancer Lifestyle Trial. Nutr Cancer. 2007; 58(1):35-42. PMID: 17571965.
      View in: PubMed
    303. Hom JJ, Coakley FV, Simko JP, Lu Y, Qayyum A, Westphalen AC, Schmitt LD, Carroll P, Kurhanewicz J. High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features--initial experience. Radiology. 2007 Feb; 242(2):483-9. PMID: 17179396.
      View in: PubMed
    304. Latini DM, Chan JM, Cowan JE, Arredondo SA, Kane CJ, Penson DF, DuChane J, Carroll P. Health-related quality of life for men with prostate cancer and diabetes: a longitudinal analysis from CaPSURE. Urology. 2006 Dec; 68(6):1242-7. PMID: 17141841.
      View in: PubMed
    305. Paris PL, Hofer MD, Albo G, Kuefer R, Gschwend JE, Hautmann RE, Fridyland J, Simko J, Carroll P, Rubin MA, Collins C. Genomic profiling of hormone-naïve lymph node metastases in patients with prostate cancer. Neoplasia. 2006 Dec; 8(12):1083-9. PMID: 17217626; PMCID: PMC1783716.
    306. Tsai HK, Chen MH, McLeod DG, Carroll P, Richie JP, D'Amico AV. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer. 2006 Dec 01; 107(11):2597-603. PMID: 17039498.
      View in: PubMed
    307. Thompson IM, Carroll P, Carducci MA. Recommendations for defining and treating high risk localized prostate cancer. J Urol. 2006 Dec; 176(6 Pt 2):S6-S10; quiz S3-5. PMID: 17084170.
      View in: PubMed
    308. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC, Amling CL, Terris MK, Aronson WJ, Kane CJ, Carroll P. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer. 2006 Nov 15; 107(10):2384-91. PMID: 17039503.
      View in: PubMed
    309. Kawakami J, Meng MV, Sadetsky N, Latini DM, Duchane J, Carroll P. Changing patterns of pelvic lymphadenectomy for prostate cancer: results from CaPSURE. J Urol. 2006 Oct; 176(4 Pt 1):1382-6. PMID: 16952638.
      View in: PubMed
    310. Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol. 2006 Sep-Oct; 24(5):396-402. PMID: 16962488.
      View in: PubMed
    311. Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll P, Moul JW, Roehl KA, D'Amico AV. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology. 2006 Aug; 68(2):342-7. PMID: 16904449.
      View in: PubMed
    312. Meng MV, Elkin EP, DuChane J, Carroll P. Impact of increased number of biopsies on the nature of prostate cancer identified. J Urol. 2006 Jul; 176(1):63-8; discussion 69. PMID: 16753368.
      View in: PubMed
    313. Eisenberg MS, Meng MV, Master VA, Stoller ML, Rini BI, Carroll P, Kane CJ. Laparoscopic versus open cytoreductive nephrectomy in advanced renal-cell carcinoma. J Endourol. 2006 Jul; 20(7):504-8. PMID: 16859465.
      View in: PubMed
    314. Swanson MG, Zektzer AS, Tabatabai ZL, Simko J, Jarso S, Keshari KR, Schmitt L, Carroll P, Shinohara K, Vigneron DB, Kurhanewicz J. Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med. 2006 Jun; 55(6):1257-64. PMID: 16685733.
      View in: PubMed
    315. Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll P. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer. 2006 Apr 15; 106(8):1708-14. PMID: 16544313.
      View in: PubMed
    316. Marr PL, Elkin EP, Arredondo SA, Broering JM, DuChane J, Carroll P. Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE. J Urol. 2006 Apr; 175(4):1326-31. PMID: 16515991.
      View in: PubMed
    317. Arredondo SA, Elkin EP, Marr PL, Latini DM, DuChane J, Litwin MS, Carroll P. Impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: data from CaPSURE. Urology. 2006 Mar; 67(3):559-65. PMID: 16527580.
      View in: PubMed
    318. Carroll P. Modifying urology residency training: time to speed up or slow down? J Urol. 2006 Mar; 175(3 Pt 1):811-2. PMID: 16469555.
      View in: PubMed
    319. Latini DM, Elkin EP, Cooperberg MR, Sadetsky N, Duchane J, Carroll P. Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE. Cancer. 2006 Feb 15; 106(4):789-95. PMID: 16400651.
      View in: PubMed
    320. Greene KL, Elkin EP, Karapetian A, Duchane J, Carroll P, Kane CJ. Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: results from CaPSURE. J Urol. 2006 Jan; 175(1):125-9; discussion 129. PMID: 16406887.
      View in: PubMed
    321. Hom JJ, Coakley FV, Simko JP, Qayyum A, Lu Y, Schmitt L, Carroll P, Kurhanewicz J. Prostate cancer: endorectal MR imaging and MR spectroscopic imaging--distinction of true-positive results from chance-detected lesions. Radiology. 2006 Jan; 238(1):192-9. PMID: 16373767.
      View in: PubMed
    322. Enokida H, Shiina H, Urakami S, Terashima M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll P, Igawa M, Dahiya R. Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma. Cancer. 2006 Jan 01; 106(1):79-86. PMID: 16323173.
      View in: PubMed
    323. Daubenmier JJ, Weidner G, Marlin R, Crutchfield L, Dunn-Emke S, Chi C, Gao B, Carroll P, Ornish D. Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance. Urology. 2006 Jan; 67(1):125-30. PMID: 16413347.
      View in: PubMed
    324. Carroll P, Coakley FV, Kurhanewicz J. Magnetic resonance imaging and spectroscopy of prostate cancer. Rev Urol. 2006; 8 Suppl 1:S4-S10. PMID: 17021625; PMCID: PMC1578527.
    325. Cooperberg MR, Moul JW, Carroll P. The changing face of prostate cancer. J Clin Oncol. 2005 Nov 10; 23(32):8146-51. PMID: 16278465.
      View in: PubMed
    326. Bassett WW, Cooperberg MR, Sadetsky N, Silva S, DuChane J, Pasta DJ, Chan JM, Anast JW, Carroll P, Kane CJ. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology. 2005 Nov; 66(5):1060-5. PMID: 16286124.
      View in: PubMed
    327. Park S, Meng MV, Elkin EP, Speight JL, DuChane J, Carroll P. Androgen deprivation use with external beam radiation for prostate cancer: results from CaPSURE. J Urol. 2005 Nov; 174(5):1802-7. PMID: 16217291.
      View in: PubMed
    328. Master VA, Chi T, Simko JP, Weinberg V, Carroll P. The independent impact of extended pattern biopsy on prostate cancer stage migration. J Urol. 2005 Nov; 174(5):1789-93; discussion 1793. PMID: 16217288.
      View in: PubMed
    329. Greene KL, Cowan JE, Cooperberg MR, Meng MV, DuChane J, Carroll P. Who is the average patient presenting with prostate cancer? Urology. 2005 Nov; 66(5 Suppl):76-82. PMID: 16194711.
      View in: PubMed
    330. Ogishima T, Shiina H, Breault JE, Terashima M, Honda S, Enokida H, Urakami S, Tokizane T, Kawakami T, Ribeiro-Filho LA, Fujime M, Kane CJ, Carroll P, Igawa M, Dahiya R. Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer. Oncogene. 2005 Oct 13; 24(45):6765-72. PMID: 16007175.
      View in: PubMed
    331. Haqq C, Li R, Khodabakhsh D, Frolov A, Ginzinger D, Thompson T, Wheeler T, Carroll P, Ayala G. Ethnic and racial differences in prostate stromal estrogen receptor alpha. Prostate. 2005 Oct 01; 65(2):101-9. PMID: 15880569.
      View in: PubMed
    332. Zhou P, Chen MH, McLeod D, Carroll P, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005 Oct 01; 23(28):6992-8. PMID: 16192586.
      View in: PubMed
    333. Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, Pejavar S, Mehta K, Carroll P, Simko JP, Waldman FM. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):7012-22. PMID: 16203795.
      View in: PubMed
    334. Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll P, Moul JW, D'Amico AV. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol. 2005 Sep 20; 23(27):6556-60. PMID: 16170163.
      View in: PubMed
    335. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll P, Dahiya R. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6582-8. PMID: 16166436.
      View in: PubMed
    336. Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ, Dunn-Emke S, Crutchfield L, Jacobs FN, Barnard RJ, Aronson WJ, McCormac P, McKnight DJ, Fein JD, Dnistrian AM, Weinstein J, Ngo TH, Mendell NR, Carroll P. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol. 2005 Sep; 174(3):1065-9; discussion 1069-70. PMID: 16094059.
      View in: PubMed
    337. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Pookot D, Li LC, Tabatabai ZL, Kawahara M, Nakagawa M, Kane CJ, Carroll P, Dahiya R. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. Int J Cancer. 2005 Aug 20; 116(2):174-81. PMID: 15800905.
      View in: PubMed
    338. Master VA, Gottschalk AR, Kane C, Carroll P. Management of isolated renal fossa recurrence following radical nephrectomy. J Urol. 2005 Aug; 174(2):473-7; discussion 477. PMID: 16006867.
      View in: PubMed
    339. Rosenberg JE, Carroll P, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol. 2005 Jul; 174(1):14-20. PMID: 15947569.
      View in: PubMed
    340. Langenstroer P, Carroll P, Thrasher JB. Clinical and pathological characteristics of unstageable prostate cancer: analysis of the CaPSURE database. J Urol. 2005 Jul; 174(1):118-20. PMID: 15947594.
      View in: PubMed
    341. Zhao H, Shiina H, Greene KL, Li LC, Tanaka Y, Kishi H, Igawa M, Kane CJ, Carroll P, Dahiya R. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer. Cancer. 2005 Jul 01; 104(1):44-52. PMID: 15895377.
      View in: PubMed
    342. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Carroll P, Waldman FM. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res. 2005 Jun 01; 11(11):4044-55. PMID: 15930339.
      View in: PubMed
    343. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll P. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005 Jun; 173(6):1938-42. PMID: 15879786; PMCID: PMC2948569.
    344. Meng MV, Elkin EP, Latini DM, Duchane J, Carroll P. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol. 2005 May; 173(5):1557-61. PMID: 15821485.
      View in: PubMed
    345. D'Amico AV, Moul J, Carroll P, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. J Urol. 2005 May; 173(5):1572-6. PMID: 15821488.
      View in: PubMed
    346. Carducci MA, Carroll P. Multidisciplinary management of advanced prostate cancer: changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials. Urology. 2005 May; 65(5 Suppl):18-22; discussion 22. PMID: 15885275.
      View in: PubMed
    347. Carroll P. Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both? J Urol. 2005 Apr; 173(4):1061-2. PMID: 15758699.
      View in: PubMed
    348. Anast JW, Sadetsky N, Pasta DJ, Bassett WW, Latini D, DuChane J, Chan JM, Cooperberg MR, Carroll P, Kane CJ. The impact of obesity on health related quality of life before and after radical prostatectomy (data from CaPSURE). J Urol. 2005 Apr; 173(4):1132-8. PMID: 15758721.
      View in: PubMed
    349. Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ, Carroll P. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol. 2005 Apr; 173(4):1126-31. PMID: 15758720.
      View in: PubMed
    350. Retz MM, Sidhu SS, Blaveri E, Kerr SC, Dolganov GM, Lehmann J, Carroll P, Simko J, Waldman FM, Basbaum C. CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells. Int J Cancer. 2005 Mar 20; 114(2):182-9. PMID: 15540205.
      View in: PubMed
    351. Shiina H, Breault JE, Basset WW, Enokida H, Urakami S, Li LC, Okino ST, Deguchi M, Kaneuchi M, Terashima M, Yoneda T, Shigeno K, Carroll P, Igawa M, Dahiya R. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer. Cancer Res. 2005 Mar 15; 65(6):2130-8. PMID: 15781623.
      View in: PubMed
    352. Sheriff SK, Shohara RA, Dumican SB, Small EJ, Carroll P, Chan JM. Lifestyle correlates of health perception and treatment satisfaction in a clinical cohort of men with prostate cancer. Clin Prostate Cancer. 2005 Mar; 3(4):239-45. PMID: 15882480.
      View in: PubMed
    353. Kane CJ, Bassett WW, Sadetsky N, Silva S, Wallace K, Pasta DJ, Cooperberg MR, Chan JM, Carroll P. Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. J Urol. 2005 Mar; 173(3):732-6. PMID: 15711258.
      View in: PubMed
    354. Sadetsky N, Lubeck DP, Latini DM, Pasta DJ, Kawakami J, DuChane J, Carroll P. Demographics, insurance coverage, and utilization of medical services in newly diagnosed prostate cancer: data from caPSURE. Manag Care Interface. 2005 Feb; 18(2):25-30. PMID: 15766061.
      View in: PubMed
    355. Li LC, Carroll P, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst. 2005 Jan 19; 97(2):103-15. PMID: 15657340.
      View in: PubMed
    356. Breault JE, Shiina H, Igawa M, Ribeiro-Filho LA, Deguchi M, Enokida H, Urakami S, Terashima M, Nakagawa M, Kane CJ, Carroll P, Dahiya R. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):557-64. PMID: 15701841.
      View in: PubMed
    357. Kawakami T, Shiina H, Igawa M, Deguchi M, Nakajima K, Ogishima T, Tokizane T, Urakami S, Enokida H, Miura K, Ishii N, Kane CJ, Carroll P, Dahiya R. Inactivation of the hMSH3 mismatch repair gene in bladder cancer. Biochem Biophys Res Commun. 2004 Dec 17; 325(3):934-42. PMID: 15541380.
      View in: PubMed
    358. Master VA, Shinohara K, Carroll P. Ferromagnetic thermal ablation of locally recurrent prostate cancer: prostate specific antigen results and immediate/intermediate morbidities. J Urol. 2004 Dec; 172(6 Pt 1):2197-202. PMID: 15538231.
      View in: PubMed
    359. Zhao H, Li LC, Okino ST, Kane CJ, Carroll P, Dahiya R. Kidney gene database: a curated and integrated database of genes involved in kidney disease. J Urol. 2004 Dec; 172(6 Pt 1):2344-6. PMID: 15538263.
      View in: PubMed
    360. Jung JA, Coakley FV, Vigneron DB, Swanson MG, Qayyum A, Weinberg V, Jones KD, Carroll P, Kurhanewicz J. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology. 2004 Dec; 233(3):701-8. PMID: 15564406.
      View in: PubMed
    361. Speight JL, Elkin EP, Pasta DJ, Silva S, Lubeck DP, Carroll P, Litwin MS. Longitudinal assessment of changes in sexual function and bother in patients treated with external beam radiotherapy or brachytherapy, with and without neoadjuvant androgen ablation: data from CaPSURE. Int J Radiat Oncol Biol Phys. 2004 Nov 15; 60(4):1066-75. PMID: 15519776.
      View in: PubMed
    362. Arredondo SA, Downs TM, Lubeck DP, Pasta DJ, Silva SJ, Wallace KL, Carroll P. Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J Urol. 2004 Nov; 172(5 Pt 1):1830-4. PMID: 15540732.
      View in: PubMed
    363. Chan JM, Jou RM, Carroll P. The relative impact and future burden of prostate cancer in the United States. J Urol. 2004 Nov; 172(5 Pt 2):S13-6; discussion S17. PMID: 15535436.
      View in: PubMed
    364. Carroll P, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PW. Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. J Urol. 2004 Nov; 172(5 Pt 2):S3-5. PMID: 15535434.
      View in: PubMed
    365. D'Amico AV, Moul J, Carroll P, Sun L, Lubeck D, Chen MH. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol. 2004 Nov; 172(5 Pt 2):S42-6; discussion S46-7. PMID: 15535442.
      View in: PubMed
    366. Carroll P. The impact of patient advocacy: the University of California-San Francisco experience. J Urol. 2004 Nov; 172(5 Pt 2):S58-61; discussion S61-2. PMID: 15535445.
      View in: PubMed
    367. Watson JE, Kamkar S, James K, Kowbel D, Andaya A, Paris PL, Simko J, Carroll P, McAlhany S, Rowley D, Collins C. Molecular analysis of WFDC1/ps20 gene in prostate cancer. Prostate. 2004 Oct 01; 61(2):192-9. PMID: 15305342.
      View in: PubMed
    368. Qayyum A, Coakley FV, Lu Y, Olpin JD, Wu L, Yeh BM, Carroll P, Kurhanewicz J. Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol. 2004 Oct; 183(4):1079-83. PMID: 15385308.
      View in: PubMed
    369. Cooperberg MR, Park S, Carroll P. Prostate cancer 2004: insights from national disease registries. Oncology (Williston Park). 2004 Sep; 18(10):1239-47; discussion 1248-50, 1256-8. PMID: 15526829.
      View in: PubMed
    370. Enokida H, Shiina H, Igawa M, Ogishima T, Kawakami T, Bassett WW, Anast JW, Li LC, Urakami S, Terashima M, Verma M, Kawahara M, Nakagawa M, Kane CJ, Carroll P, Dahiya R. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res. 2004 Sep 01; 64(17):5956-62. PMID: 15342374.
      View in: PubMed
    371. Sasaki M, Nomoto M, Yonezawa S, Nakagawa M, Sakuragi N, Fujimoto S, Carroll P, Dahiya R. Distribution of a single nucleotide polymorphism on codon 211 of the androgen receptor gene and its correlation with human renal cell cancer in Japanese patients. Biochem Biophys Res Commun. 2004 Aug 20; 321(2):468-71. PMID: 15358199.
      View in: PubMed
    372. Li LC, Shiina H, Deguchi M, Zhao H, Okino ST, Kane CJ, Carroll P, Igawa M, Dahiya R. Age-dependent methylation of ESR1 gene in prostate cancer. Biochem Biophys Res Commun. 2004 Aug 20; 321(2):455-61. PMID: 15358197.
      View in: PubMed
    373. Greene KL, Meng MV, Elkin EP, Cooperberg MR, Pasta DJ, Kattan MW, Wallace K, Carroll P. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure). J Urol. 2004 Jun; 171(6 Pt 1):2255-9. PMID: 15126797.
      View in: PubMed
    374. Cooperberg MR, Broering JM, Latini DM, Litwin MS, Wallace KL, Carroll P. Patterns of practice in the United States: insights from CaPSURE on prostate cancer management. Curr Urol Rep. 2004 Jun; 5(3):166-72. PMID: 15161564.
      View in: PubMed
    375. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll P. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004 Jun 01; 22(11):2141-9. PMID: 15169800; PMCID: PMC2997214.
    376. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JE, Volik S, Albertson DG, Pinkel D, Alers JC, van der Kwast TH, Vissers KJ, Schroder FH, Wildhagen MF, Febbo PG, Chinnaiyan AM, Pienta KJ, Carroll P, Rubin MA, Collins C, van Dekken H. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet. 2004 Jul 01; 13(13):1303-13. PMID: 15138198.
      View in: PubMed
    377. Moyad MA, Carroll P. Lifestyle recommendations to prevent prostate cancer, part I: time to redirect our attention? Urol Clin North Am. 2004 May; 31(2):289-300. PMID: 15123408.
      View in: PubMed
    378. Moyad MA, Carroll P. Lifestyle recommendations to prevent prostate cancer, part II: time to redirect our attention? Urol Clin North Am. 2004 May; 31(2):301-11. PMID: 15123409.
      View in: PubMed
    379. D'Amico AV, Moul JW, Carroll P, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst. 2004 Apr 07; 96(7):509-15. PMID: 15069112.
      View in: PubMed
    380. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll P. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004 Apr; 171(4):1393-401. PMID: 15017184.
      View in: PubMed
    381. Strohmeyer DM, Berger AP, Moore DH, Bartsch G, Klocker H, Carroll P, Loening SA, Jensen RH. Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis: association with progression and angiogenesis. Prostate. 2004 Apr 01; 59(1):43-58. PMID: 14991865.
      View in: PubMed
    382. Cooperberg MR, Downs TM, Carroll P. Radical retropubic prostatectomy frustrated by prior laparoscopic mesh herniorrhaphy. Surgery. 2004 Apr; 135(4):452-3; discussion 454. PMID: 15041971.
      View in: PubMed
    383. Master VA, Meng MV, Grossfeld GD, Koppie TM, Hirose R, Carroll P. Treatment and outcome of invasive bladder cancer in patients after renal transplantation. J Urol. 2004 Mar; 171(3):1085-8. PMID: 14767276.
      View in: PubMed
    384. Yun EJ, Meng MV, Carroll P. Evaluation of the patient with hematuria. Med Clin North Am. 2004 Mar; 88(2):329-43. PMID: 15049581.
      View in: PubMed
    385. Hu JC, Elkin EP, Pasta DJ, Lubeck DP, Kattan MW, Carroll P, Litwin MS. Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol. 2004 Feb; 171(2 Pt 1):703-7; discussion 707-8. PMID: 14713791.
      View in: PubMed
    386. Kane CJ, Mitchell JA, Meng MV, Anast J, Carroll P, Stoller ML. Laparoscopic partial nephrectomy with temporary arterial occlusion: description of technique and renal functional outcomes. Urology. 2004 Feb; 63(2):241-6. PMID: 14972462.
      View in: PubMed
    387. Dhingsa R, Qayyum A, Coakley FV, Lu Y, Jones KD, Swanson MG, Carroll P, Hricak H, Kurhanewicz J. Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiology. 2004 Jan; 230(1):215-20. PMID: 14695396.
      View in: PubMed
    388. Mehta SS, Lubeck DP, Sadetsky N, Pasta DJ, Carroll P. Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE. J Urol. 2004 Jan; 171(1):215-9. PMID: 14665879.
      View in: PubMed
    389. Sasaki M, Kaneuchi M, Sakuragi N, Fujimoto S, Carroll P, Dahiya R. The polyglycine and polyglutamine repeats in the androgen receptor gene in Japanese and Caucasian populations. Biochem Biophys Res Commun. 2003 Dec 26; 312(4):1244-7. PMID: 14652007.
      View in: PubMed
    390. Carroll P, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M, Sellers WR, Smith MR, McMann MC, Kantoff PW. Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. J Urol. 2003 Dec; 170(6 Pt 2):S3-5. PMID: 14610403.
      View in: PubMed
    391. Kane CJ, Lubeck DP, Knight SJ, Spitalny M, Downs TM, Grossfeld GD, Pasta DJ, Mehta SS, Carroll P. Impact of patient educational level on treatment for patients with prostate cancer: data from CaPSURE. Urology. 2003 Dec; 62(6):1035-9. PMID: 14665350.
      View in: PubMed
    392. Meng MV, Elkin EP, Harlan SR, Mehta SS, Lubeck DP, Carroll P. Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE. J Urol. 2003 Dec; 170(6 Pt 1):2279-83. PMID: 14634396.
      View in: PubMed
    393. Cooperberg MR, Lubeck DP, Mehta SS, Carroll P. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003 Dec; 170(6 Pt 2):S21-5; discussion S26-7. PMID: 14610406.
      View in: PubMed
    394. Downs TM, Sadetsky N, Pasta DJ, Grossfeld GD, Kane CJ, Mehta SS, Carroll P, Lubeck DP. Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer--data from CaPSURE. J Urol. 2003 Nov; 170(5):1822-7. PMID: 14532784.
      View in: PubMed
    395. Harlan SR, Cooperberg MR, Elkin E, Lubeck DP, Meng M, Mehta SS, Carroll P. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol. 2003 Nov; 170(5):1804-7. PMID: 14532780.
      View in: PubMed
    396. Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll P, James JK, Hurd RE, Kurhanewicz J. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med. 2003 Nov; 50(5):944-54. PMID: 14587005.
      View in: PubMed
    397. D'Amico AV, Moul JW, Carroll P, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003 Sep 17; 95(18):1376-83. PMID: 13130113.
      View in: PubMed
    398. Cooperberg M, Lubeck DP, Penson D, Mehta SS, Carroll P, Kane CJ. Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. J Urol. 2003 Sep; 170(3):905-8. PMID: 12913727.
      View in: PubMed
    399. Staack A, Donjacour AA, Brody J, Cunha GR, Carroll P. Mouse urogenital development: a practical approach. Differentiation. 2003 Sep; 71(7):402-13. PMID: 12969333.
      View in: PubMed
    400. Cooperberg MR, Master VA, Carroll P. Health related quality of life significance of single pad urinary incontinence following radical prostatectomy. J Urol. 2003 Aug; 170(2 Pt 1):512-5. PMID: 12853811.
      View in: PubMed
    401. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll P. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003 Jul 02; 95(13):981-9. PMID: 12837834; PMCID: PMC2994265.
    402. D'Amico AV, Moul J, Carroll P, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003 Jun 01; 21(11):2163-72. PMID: 12775742.
      View in: PubMed
    403. Veltman JA, Fridlyand J, Pejavar S, Olshen AB, Korkola JE, DeVries S, Carroll P, Kuo WL, Pinkel D, Albertson D, Cordon-Cardo C, Jain AN, Waldman FM. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res. 2003 Jun 01; 63(11):2872-80. PMID: 12782593.
      View in: PubMed
    404. Purohit RS, Shinohara K, Meng MV, Carroll P. Imaging clinically localized prostate cancer. Urol Clin North Am. 2003 May; 30(2):279-93. PMID: 12735504.
      View in: PubMed
    405. Patra SK, Patra A, Zhao H, Carroll P, Dahiya R. Methyl-CpG-DNA binding proteins in human prostate cancer: expression of CXXC sequence containing MBD1 and repression of MBD2 and MeCP2. Biochem Biophys Res Commun. 2003 Mar 21; 302(4):759-66. PMID: 12646234.
      View in: PubMed
    406. Paris PL, Albertson DG, Alers JC, Andaya A, Carroll P, Fridlyand J, Jain AN, Kamkar S, Kowbel D, Krijtenburg PJ, Pinkel D, Schröder FH, Vissers KJ, Watson VJ, Wildhagen MF, Collins C, Van Dekken H. High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays. Am J Pathol. 2003 Mar; 162(3):763-70. PMID: 12598311; PMCID: PMC1868117.
    407. Staack A, Kassis AP, Olshen A, Wang Y, Wu D, Carroll P, Grossfeld GD, Cunha GR, Hayward SW. Quantitation of apoptotic activity following castration in human prostatic tissue in vivo. Prostate. 2003 Feb 15; 54(3):212-9. PMID: 12518326.
      View in: PubMed
    408. Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll P. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol. 2003 Jan; 169(1):157-63. PMID: 12478126.
      View in: PubMed
    409. Cooperberg MR, Koppie TM, Lubeck DP, Ye J, Grossfeld GD, Mehta SS, Carroll P. How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: data from CaPSURE. Urology. 2003 Jan; 61(1):190-6. PMID: 12559294.
      View in: PubMed
    410. Grossfeld GD, Latini DM, Downs T, Lubeck DP, Mehta SS, Carroll P. Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy? J Urol. 2002 Dec; 168(6):2510-5. PMID: 12441951.
      View in: PubMed
    411. Powell IJ, Tangen CM, Miller GJ, Lowe BA, Haas G, Carroll P, Osswald MB, DeVERE WHITE R, Thompson IM, Crawford ED. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109. J Urol. 2002 Nov; 168(5):2016-9. PMID: 12394698.
      View in: PubMed
    412. Katz D, Koppie TM, Wu D, Meng MV, Grossfeld GD, Sadesky N, Lubeck DP, Carroll P. Sociodemographic characteristics and health related quality of life in men attending prostate cancer support groups. J Urol. 2002 Nov; 168(5):2092-6. PMID: 12394716.
      View in: PubMed
    413. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll P. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):7-11; discussion 11-2. PMID: 12231037.
      View in: PubMed
    414. Grossfeld GD, Li YP, P Lubeck DP, Carroll P. Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy. Urology. 2002 Sep; 60(3 Suppl 1):57-62; discussion 62-3. PMID: 12231051.
      View in: PubMed
    415. Carroll P, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):1-6. PMID: 12231036.
      View in: PubMed
    416. Lubeck DP, Grossfeld GD, Carroll P. A review of measurement of patient preferences for treatment outcomes after prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):72-7; discussion 77-8. PMID: 12231054.
      View in: PubMed
    417. Grossfeld GD, Li YP, Lubeck DP, Broering JM, Mehta SS, Carroll P. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. J Urol. 2002 Aug; 168(2):530-5. PMID: 12131303.
      View in: PubMed
    418. Meng MV, Grossfeld GD, Carroll P, Small EJ. Neoadjuvant strategies for prostate cancer prior to radical prostatectomy. Semin Urol Oncol. 2002 Aug; 20(3 Suppl 1):10-8. PMID: 12198633.
      View in: PubMed
    419. Ribeiro-Filho LA, Franks J, Sasaki M, Shiina H, Li LC, Nojima D, Arap S, Carroll P, Enokida H, Nakagawa M, Yonezawa S, Dahiya R. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Mol Carcinog. 2002 Aug; 34(4):187-98. PMID: 12203370.
      View in: PubMed
    420. Cooperberg MR, Lubeck DP, Grossfeld GD, Mehta SS, Carroll P. Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor. J Urol. 2002 Aug; 168(2):491-5. PMID: 12131295.
      View in: PubMed
    421. Litwin MS, Lubeck DP, Spitalny GM, Henning JM, Carroll P. Mental health in men treated for early stage prostate carcinoma: a posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer. 2002 Jul 01; 95(1):54-60. PMID: 12115317.
      View in: PubMed
    422. Elliott SP, Shinohara K, Logan SL, Carroll P. Sextant prostate biopsies predict side and sextant site of extracapsular extension of prostate cancer. J Urol. 2002 Jul; 168(1):105-9. PMID: 12050501.
      View in: PubMed
    423. Master VA, Meng MV, Koppie TM, Carroll P, Grossfeld GD. Origin of urothelial carcinoma after renal transplant determined by fluorescence in situ hybridization. J Urol. 2002 Jun; 167(6):2521-2. PMID: 11992074.
      View in: PubMed
    424. Goharderakhshan RZ, Sudilovsky D, Carroll LA, Grossfeld GD, Marn R, Carroll P. Utility of intraoperative frozen section analysis of surgical margins in region of neurovascular bundles at radical prostatectomy. Urology. 2002 May; 59(5):709-14. PMID: 11992845.
      View in: PubMed
    425. Penson DF, Grossfeld GD, Li YP, Henning JM, Lubeck DP, Carroll P. How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. J Urol. 2002 Apr; 167(4):1653-7; discussion 1657-8. PMID: 11912382.
      View in: PubMed
    426. Grossfeld GD, Latini DM, Lubeck DP, Broering JM, Li YP, Mehta SS, Carroll P. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE. Urology. 2002 Apr; 59(4):560-5. PMID: 11927314.
      View in: PubMed
    427. Coakley FV, Kurhanewicz J, Lu Y, Jones KD, Swanson MG, Chang SD, Carroll P, Hricak H. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology. 2002 Apr; 223(1):91-7. PMID: 11930052.
      View in: PubMed
    428. Grossfeld GD, Carroll P, Lindeman N, Meng M, Groshen S, Feng AC, Hawes D, Cote RJ. Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression. Urology. 2002 Jan; 59(1):97-102. PMID: 11796289.
      View in: PubMed
    429. Downs TM, Kane CJ, Grossfeld GD, Meng MV, Carroll P. Surgery for prostate cancer: rationale, technique and outcomes. Cancer Metastasis Rev. 2002; 21(1):29-44. PMID: 12400995.
      View in: PubMed
    Peter's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _